• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    FGFR inhibitors for use in the treatment of lung cancer. The present invention describes a method for predicting the response of a subject suffering from lung cancer to treatment with FGFR inhibitors. The relationship of the expression of the biomarkers described with the response to treatment, allows classifying the subjects as responders or non-responders to treatment, which facilitates the therapeutic decision to the clinician. The present method describes the biomarkers N-cadherin, FGFR1 and FGFR4, how to analyze them and how to interpret the results obtained, in order to administer FGFR inhibitors only to the subjects that will respond to said treatment, optimizing it, which allows that non-responder subjects can be treated with alternative therapies to that of FGFR inhibitors. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2696798A1
    申请号:ES201730929
    申请日:2017-07-13
    公开日:2019-01-17
    发明作者:Rodríguez Luis Paz-Ares；Villalonga Alvaro Quintanal；Sánchez Irene Ferrer；Pinelo Sonia Molina；Moya Amancio Carnero
    申请人:Fundacion De Investig Hospital 12 De Octubre；Servicio Andaluz De Salud Sas；Consejo Superior de Investigaciones Cientificas CSIC；
    IPC主号:
    专利说明:

    [0001] FGFR INHIBITORS FOR USE IN THE TREATMENT OF LUNG CANCER
    [0002]
    [0003] SECTOR OF THE TECHNIQUE
    [0004]
    [0005] The present invention belongs to the field of clinical medicine and, more specifically, to the treatment of lung cancer with anti-FGFR drugs.
    [0006]
    [0007] The main object of the present invention is the use of the biomarkers N-cadherin and FGFR1 and / or FGFR4 in the prognosis and prediction of the response of a subject suffering from lung cancer to treatment with FGFR inhibitors.
    [0008]
    [0009] BACKGROUND OF THE INVENTION
    [0010]
    [0011] Lung cancer is a group of diseases resulting from the malignant growth of cells of the respiratory tract, in particular lung tissue and one of the most frequent cancers worldwide. Because most patients are diagnosed in advanced stages of the disease, the survival rate is very low. Lung cancer usually originates from epithelial cells and can lead to metastasis and infiltration to other tissues of the body. Although FGFR inhibitors have been used in clinical trials in the treatment of lung cancer, many of the patients do not respond to these therapies.
    [0012]
    [0013] Being able to determine if a treatment is going to be efficient or not for a certain patient before administering it will benefit the patient, since it will prevent the patient from unnecessarily suffering the side effects of an ineffective treatment, prioritizing the search for alternative treatments more quickly and saving costs in the treatment and improving, in addition, the expectations of an effective response.
    [0014]
    [0015] The identification of new biomarkers that can predict the response of a patient to a treatment is decisive in the clinical treatment of any pathology. The application of high performance technologies in lung cancer has identified multiple alterations in genes with a potential role in this type of cancer. Many of these alterations take place in proteins with tyrosine kinase activity (Quintanal-Villalonga 2016).
    [0016]
    [0017] Fibroblast growth factor receptors (FGFRs) are membrane receptors with tyrosine kinase activity that bind to members of the fibroblast growth factor family. The activation of FGFRs is related to the regulation of cell survival, proliferation, migration and differentiation. It has been described that deregulation of signaling pathways of FGFRs is associated with cancer in humans (Wesche 2011), so they represent an important therapeutic target in cancer. Five members of the FGFR receptor family have been identified (FGFR1, FGFR2, FGFR3, FGFR4 and FGFRL1).
    [0018]
    [0019] FGFR inhibitors have been used successfully in preclinical models of different types of cancer. However, at the clinical level these inhibitors do not present efficacy in all patients, although these have been previously selected with the current criteria predictive of sensitivity to these inhibitors. The criteria for patient selection to access clinical trials with FGFR inhibitors have generally been aimed at detecting the amplification of some FGFR, but unfortunately these criteria have shown that their ability to predict the response to treatment is not totally reliable. which results in a problem in the treatment of patients suffering from cancer. Preliminary results from clinical trials have shown that many of the tumors in which the FGFR1 gene is amplified do not respond to FGFR receptor-directed therapy, suggesting that other biomarkers are necessary to correctly stratify patients and predict their response to this type of therapy. The objective of the present invention is to determine whether a patient suffering from lung cancer will respond to treatment with FGFR inhibitors.
    [0020]
    [0021] It has been observed that in lung cancer, approximately 20% of squamous cell carcinomas and in 1-3% of adenocarcinomas, the FGFR1 gene is amplified. On the other hand, it is known that the FGFR4 gene has mutations in some patients with adenocarcinoma and that, in addition, the expression of the FGFR4 receptor has been related to a worse prognosis in non-small cell lung cancer. These data, together with different preclinical studies in this pathology, suggest that both genes could have great relevance in lung cancer (Dutt, 2011, Jiang, 2015, Huang, 2015, Lim, 2016).
    [0022]
    [0023] The use of FGFR inhibitors in the treatment of lung cancer has also been described in patients with high expression levels of FGFR1 (US2015335643A1 and US8709718B1).
    [0024] Neural cadherin (NCAD), N-cadherin or Cadherin-2 (CDH2) is a transmembrane glycoprotein responsible for cell-cell binding encoded by the CDH2 gene . It plays an important role during development, in the cells of the central nervous system, cardiac muscle, but also in the metastasis of cancer. In turn, it plays an important role in the mediation of neural signals. N-cadherin positively regulates the activation of FGFR in tumor cells, increasing the invasive activity of tumor cells and favoring the progression of metastasis in preclinical models of some types of cancer (Qian 2014; Nguyen 2016).
    [0025]
    [0026] It has been found in bladder cancer that mRNA levels of epithelial-mesenchymal transition markers, such as E-cadherin and N-cadherin, could be used together to predict the response to treatment with a FGFR inhibitor (TKI-258) , because mesenchymal bladder cancer cell lines are more responsive than epithelial type cell lines (Hanze 2013).
    [0027]
    [0028] But what has not been described in the state of the art and no document suggests, is the relationship between the level of expression of N-cadherin on the one hand and the level of expression of FGFR1 and / or FGFR4 on the other, as biomarkers, for To determine if treatment with FGFR inhibitors is effective in a patient suffering from lung cancer. The present invention shows for the first time the therapeutic relevance of N-cadherin in the tumorigenic role of FGFR1 and FGFR4 in lung cancer.
    [0029]
    [0030] DESCRIPTION OF THE INVENTION
    [0031]
    [0032] BRIEF DESCRIPTION OF THE INVENTION
    [0033]
    [0034] In one embodiment, the present invention relates to an in vitro method for predicting the response of a subject suffering from lung cancer to a treatment with at least one FGFR inhibitor, comprising:
    [0035] a) detecting in a biological sample obtained from said subject the levels of the biomarker N-cadherin in combination with the expression of at least one of the biomarkers FGFR1 and / or FGFR4,
    [0036] b) comparing the level of expression of the biomarkers determined in (a) with a reference sample, in which high levels of the detected markers, is indicative that the subject will respond to the treatment.
    [0037]
    [0038] In a more preferred embodiment, the determination of the expression level of biomarkers in the in vitro method is performed by measuring the amount of N-cadherin protein and the amount of FGFR1 and / or FGFR4 protein in the sample, or by measuring the amount of mRNA of the CDH2 gene and the amount of mRNA of the FGFR1 and / or FGFR4 genes in the sample.
    [0039]
    [0040] In another preferred embodiment, lung cancer is non-small cell lung cancer. In a still more preferred embodiment, the non-small cell lung cancer is selected from adenocarcinoma and squamous or squamous cell carcinoma.
    [0041] In another embodiment of the invention, the biological sample analyzed in step a) in the in vitro method according to any of the preceding embodiments is selected from the group comprising: whole blood, serum, plasma, sputum, sweat, urine, wash bronchioalveolar, biopsy of primary or metastatic tumor tissue. In a still more preferred embodiment, the biological sample is a biopsy of the primary tumor of the subject.
    [0042]
    [0043] In a preferred embodiment of the in vitro method according to any of the above embodiments, the detection of the amount of the biomarkers is performed by at least one of the methods selected from: HPLC (high performance liquid chromatography), LC / MS ( liquid chromatography coupled to mass spectrometry, ELISA, DAS ELISA, protein immunoprecipitation, immunoelectrophoresis, Western Blot, protein immunostaining, Northern Blot, reverse transcription PCR (RT-PCR), quantitative PCR (q-PCR), RIA (radioimmunoassay ), in situ hybridization , nuclease protection assay, mass sequencing, immunocytochemical or immunohistochemical techniques, genomic DNA microarrays, protein microarrays, messenger RNA microarrays, cDNA microarrays, peptide microarrays, tissue microarrays, cellular microarrays or transfection, antibody microarrays, lysate or serum microarrays, protein microarrays s of reverse phase, microarrays of peptides or genotyping microarrays, among others. In a more preferred embodiment, the detection of the mRNA of the biomarkers is carried out by PCR with reverse transcription (RT-PCR) or quantitative PCR (q-PCR).
    [0044]
    [0045] In one embodiment of the in vitro method according to any of the above embodiments, high levels of the detected biomarkers correspond to a level at least two times higher than the level of the same marker in a reference sample.
    [0046]
    [0047] In another embodiment of the method of agreement, the at least one FGFR inhibitor is selected from the group comprising BGJ398, AZD4547, Debio-1347, Dovitinib, BLU9931, FIIN-2, JNJ-42756493, LY2874455, Ponatinib, BIBF1120, PD173074 , PD166866, BLU554, S49076, NSC12, PHA-739358, TSU-68, BMS-540215, TKI-258, MK-2461, BMS-582664, AG 1296, SSR128129E, LY2874455 and SU5402.
    [0048]
    [0049] Another embodiment of the invention relates to the combination of the biomarker N-cadherin and at least one second biomarker selected from FGFR1 and / or FGFR4, for use in the prognosis and / or prediction of the response of a subject suffering from lung cancer. to treatment with FGFR inhibitors.
    [0050]
    [0051] In a more preferred embodiment of this embodiment of use, the level of expression of each biomarker is determined by measuring the mRNA level of the CDH2 and FGFR1 and / or FGFR4 genes , and / or the protein level of N-cadherin and FGFR1 and / or FGFR4.
    [0052] In a preferred embodiment of the combination of biomarkers for use, according to any of the two immediately preceding embodiments, lung cancer is a non-small cell carcinoma selected from adenocarcinoma or squamous carcinoma.
    [0053] In another embodiment, the at least one FGFR inhibitor of the combination of biomarkers for use according to any of the above use embodiments is selected from the group comprising BGJ398, AZD4547, Debio-1347, Dovitinib, BLU9931, FIIN-2, JNJ-42756493, LY2874455, Ponatinib, BIBF1120, PD173074, PD166866, BLU554, S49076, NSC12, PHA-739358, TSU-68, BMS-540215, TKI-258, MK-2461, BMS-582664, AG 1296, SSR128129E, LY2874455 and SU5402.
    [0054]
    [0055] Another embodiment of the invention relates to a kit for predicting and / or predicting the response of a subject suffering from lung cancer to a treatment with FGFR inhibitors comprising:
    [0056] (a) means for detecting in a biological sample obtained from the subject the levels of the biomarker N-cadherin, on the one hand, and the expression of at least one of the biomarkers FGFR1 and / or FGFR4 by another,
    [0057] (b) means for comparing the level of expression of the biomarkers determined in (a) with a reference sample,
    [0058] (c) instructions for a medical professional to administer treatment with FGFR inhibitors only to those subjects that show high expression of N-cadherin and also high expression of FGFR1 and / or FGFR4.
    [0059]
    [0060] In a preferred embodiment, the determination of the levels of the biomarkers in the kit is performed by measuring the amount of N-cadherin biomarker protein and the amount of protein from at least one of the biomarkers FGFR1 or FGFR4 in the sample, or by measuring the amount of mRNA of the CDH2 gene and the amount of mRNA of at least one of the FGFR1 or FGFR4 genes in the sample.
    [0061]
    [0062] In another preferred embodiment, the lung cancer sample to be analyzed in the kit is a sample of non-small cell lung cancer. In a still more preferred embodiment, the non-small cell lung cancer is selected from adenocarcinoma and squamous or squamous cell carcinoma.
    [0063]
    [0064] In a preferred embodiment of the kit according to any of the above embodiments of said kit, the means for detecting the levels of the biomarkers comprise antibodies that specifically recognize the N-cadherin proteins and antibodies that specifically recognize the FGFR1 and / or FGFR4 proteins, or primers and / or probes that specifically detect the presence of the mRNA of the CDH2 gene and in addition primers and / or probes that specifically detect the presence of the mRNA of the FGFR1 and / or FGFR4 genes .
    [0065] In another preferred embodiment of the kit according to any of the above embodiments of said kit, the biological sample is selected from the group comprising: whole blood, serum, plasma, sputum, sweat, urine, bronchoalveolar lavage, biopsy of the primary tumor tissue or metastatic
    [0066]
    [0067] In a further embodiment of the kit according to any of the above embodiments of said kit, the detection of biomarkers is carried out by at least one of the methods selected from: HPLC (high performance liquid chromatography), LC / MS (liquid chromatography) coupled to mass spectrometry, ELISA, DAS ELISA, protein immunoprecipitation, immunoelectrophoresis, Western Blot, protein immunostaining, Northern Blot, reverse transcription PCR (RT-PCR), quantitative PCR (q-PCR), RIA (radioimmunoassay), in situ hybridization , nuclease protection assay, mass sequencing, immunocytochemical or immunohistochemical techniques of genomic DNA microarrays, protein microarrays, messenger RNA microarrays, cDNA microarrays, peptide microarrays, tissue microarrays, cellular or transfection microarrays, antibody microarrays, lysate or serum microarrays, reverse phase protein microarrays sa, microarray of peptides or genotyping microarrays, among others. In a more preferred embodiment, the detection of the mRNA of the biomarkers is carried out by PCR with reverse transcription (RT-PCR) or quantitative PCR (q-PCR).
    [0068]
    [0069] Description of the Figures
    [0070]
    [0071] Figure 1. Protein expression of FGFR1 and FGFR4 in lung cancer cell lines . ADC = Adenocarcinoma, ESC = Squamous carcinoma, I = Immortalized, KRAS = KRAS mutated, EGFR = EGFR mutated, ALK = Carrier of translocations EML4-ALK, TN = Triple negative. Tubulin is used as a load control.
    [0072]
    [0073] Figure 2. Effect of overexpression of FGFR4 on epidermoid carcinoma lines . 10% growth curves with bovine fetal serum (A), clonability test (B) and anchor free growth test (C). Determination of the activation of oncogenic signaling pathways (D) in the presence or absence of SFB, in squamous cell carcinoma lines under overexpression of FGFR4. EV = empty vector, FGFR4 = overexpression of FGFR4, SFB = fetal bovine serum. The p-values are represented by asterisks (*, p <0.05; **, p <0.01; ***, p <0.001).
    [0074]
    [0075] Figure 3 Effect of silencing of FGFR1 or FGFR4 on a line of squamous cell carcinoma. Growth curves at 10% of fetal bovine serum (A), clonability (B) and anchor-free growth (C). Analysis of the activation of related signaling routes with FGFR (D) in the presence or absence of SFB. control = nonspecific shRNA, as control, shFGFR1 = shRNA FGFR1, shFGFR4 = shRNA FGFR4, SFB = Bovine fetal serum. Samples (a) and (b) correspond to two independent shRNAs to silence the same gene. The p-values are represented by asterisks (*, p <0.05; **, p <0.01; ***, p <0.001).
    [0076]
    [0077] Figure 4. Effect of overexpression of FGFR1 and FGFR4 on ADC lines. Growth curves at 10% SFB (A), clonability (B) and anchor free growth (C). Study of the activation of signaling pathways related to FGFR by western blot (D) in the presence or absence of SFB. EV = empty vector, FGFR1 = overexpression of FGFR1, FGFR4 = overexpression of FGFR4, SFB = fetal bovine serum. The p-values are represented by asterisks (*, p <0.05; **, p <0.01; ***, p <0.001).
    [0078]
    [0079] Figure 5. Effect of the silencing of FGFR1 or FGFR4 on an adenocarcinoma line not dependent on EGFR. Growth curves at 10% SFB (A), clonability (B) and anchor free growth (C). Measurement of activation of signaling pathways related to FGFR (D). Control = nonspecific shRNA, shFGFR1 = silencing of FGFR1, shFGFR4 = silencing of FGFR4, SFB = Fetal bovine serum. Samples (a) and (b) correspond to two independent shRNAs to silence the same gene. The p-values are represented by asterisks (*, p <0.05; **, p <0.01; ***, p <0.001).
    [0080]
    [0081] Figure 6. Characterization of the expression of E-cadherin and N-cadherin in lung cancer cell lines. ADC = Adenocarcinoma, ESC = Epidermoid, I = Immortalized, KRAS = KRAS mutated, EGFR = mutated EGFR, ALK = Carrier of translocation of ALK, TN = Triple negative (absence of alterations in KRAS, EGFR or ALK).
    [0082]
    [0083] Figure 7. Effect of co-overexpression of N-cadherin with FGFR1 or FGFR4 on adenocarcinoma lines. Growth curves at 10% SFB (A), clonability (B) and anchor free growth (C). Analysis of activation of signaling pathways related to FGFR (D). EV1 = empty vector 1, EV2 = empty vector 2, CDH2 = Overexpression of N-cadherin, FGFR1 = Overexpression of FGFR1, FGFR4 = Overexpression of FGFR4, SFB = Fetal bovine serum. The p-values are represented by asterisks (*, p <0.05; **, p <0.01; ***, p <0.001).
    [0084]
    [0085] Figure 8. Effect of the silencing of N-cadherin in a cell line overexpressing FGFR1 or FGFR4. Growth curves at 5% FBS (A), anchor free growth assays (B) and determination of the activation of oncogenic signaling (C). (D) Tumor growth of xenografts from the panel of stable lines generated from the immortalized lung line NL20 with different expression combinations of N-cadherin, FGFR1 or FGFR4. The p-values were obtained using the Student's T test with a confidence interval of 95% and are represented by asterisks (*, p <0.05; **, p <0.01; ***, p <0.001). EV1 = Control vector empty 1, EV2 = Control vector empty 2. FGFR1 = Overexpression of FGFR1, FGFR4 = Overexpression of FGFR4, shCDH2 = Silencing of N-cadherin.
    [0086]
    [0087] Figure 9. Interaction of N-cadherin with FGFR1 or FGFR4. (A) Co-immunolocalization assay of N-cadherin and FGFR1 or FGFR4 in the NL20 cell line with exogenous overexpression of the receptors. (B) Co-immunoprecipitation of N-cadherin with FGFR1 and FGFR4 in the H520 cell line.
    [0088]
    [0089] Figure 10. Association of the expression of N-cadherin mRNA and of FGFR1 or FGFR4 with survival in patients with non-mycotic cancer of the lung (N = 109). The criterion for discerning between low and high expression is the value of the median expression for each gene measured in 2-ACT. (A) Progression-free survival and overall survival of the cohort of patients based on their gene expression. (B) Association of N-cadherin mRNA expression with progression-free survival and overall survival in the subset of NSCLC patients with high expression of FGFR1 or FGFR4 (N = 89). NSCLC = Non-small cell lung cancer.
    [0090]
    [0091] Figure 11. Association of the expression of N-cadherin mRNA and FGFR1 and / or FGFR4 with survival in patients with adenocarcinoma. (A) Progression-free survival and overall survival of a cohort of patients with adenocarcinoma based on their gene expression. On the left are the survival curves of patients with high FGFR1 and high or low N-cadherin (N = 245) and to the right are the survival curves of patients with high FGFR4 and high or low N-cadherin ( N = 366). (B) Association of N-cadherin mRNA expression with survival in the subset of ADC-TCGA patients having high expression of FGFR1, FGFR4 or both. ADC-TCGA = Adenocarcinoma cohort of The Cancer Genome Atlas.
    [0092]
    [0093] Figure 12. Association of mRNA expression of FGFR1, FGFR4 and N-cadherin with survival in a cohort of patients with squamous cell carcinoma of TCGA (N = 504). (A) Progression-free survival and overall survival of the cohort of patients based on their gene expression. The survival curves of patients with high FGFR1 and high or low N-cadherin (N = 251) are shown to the left and the survival curves of patients with high FGFR4 and high or low N-cadherin ( N = 250). (B) Association of N-cadherin mRNA expression with survival in the subset of ESC-TCGA patients with high expression of FGFR1, FGFR4 or both (N = 373). ESC-TCGA = Cohort of squamous cell carcinoma of The Cancer Genome Atlas.
    [0094] Figure 13. Effect of in vitro treatment with selective inhibitors of FGFR in lines with high expression of FGFR1 and / or FGFR4 and differential levels of N-cadherin. (TO) Effect of treatment with FGFR inhibitors (BGJ398 and AZD4547) on the growth of adenocarcinoma and squamous cell carcinoma lines with endogenous expression of FGFR1 (H460), FGFR1 and FGFR4 (A549), FGFR1 and N-cadherin (H226) and FGFR1, FGFR4 and N-cadherin (H520). (B) Effect of treatment with FGFR inhibitors (BGJ398 and AZD4547) on the growth of adenocarcinoma lines with exogenous expression of FGFR1 or FGFR4 (upper line), or exogenous expression of N-cadherin and FGFR1 or FGFR4 (lower line).
    [0095] Figure 14 Effect of in vivo treatment with a selective inhibitor of FGFR in lung PDXs with high expression of FGFR1 and FGFR4. (A) Western blot of the expression of FGFR1, FGFR4 and N-cadherin in the PDXs under study. (B) Effect of treatment with AZD4547 on tumor models derived from patients (PDXs) low expression of N-cadherin. (C) Effect of treatment with AZD4547 on tumor models derived from patients (PDXs) high expression of N-cadherin. (D) Graph that represents the variation of the volume of the tumors with respect to the beginning of the treatment, expressed in percentages. (E) Determination by western blot of the effect of the treatment on signaling pathways related to FGFR. The p-values were obtained using the Student's T test with a confidence interval of 95% and are represented as p-values are represented by asterisks (*, p <0.05; **, p <0.01 ; ***, p <0.001). ADC = adenocarcinoma, ESC = squamous cell carcinoma.
    [0096]
    [0097] Detailed description of the invention
    [0098]
    [0099] The present invention shows that determining the expression level of N-cadherin and determining the level of expression of at least one of the biomarkers FGFR1 and / or FGFR4 improves the selection of patients for an anti-FGFR therapy in the treatment of cancer of lung. The invention shows how this model predicts the response to treatment with FGFR inhibitors of patients, according to a high expression of N-cadherin and also also a high expression of at least one of the FGFRs selected between FGFR1 and / or FGFR4. The high expression of the biomarkers FGFR1 and / or FGFR4 can be due to different events that occur in the cell, such as, but not limited to: amplification, expression induction at the transcriptional or translational level, gene translocations, etc. .
    [0100]
    [0101] The criteria currently used to include patients in clinical trials with FGFR inhibitors are the amplification of a specific FGFR, or the presence of mutations or translocations in a specific FGFR. However, the only alterations that are associated with a good response to these inhibitors are activating mutations or translocations, which constitute a very low percentage of patients. The Amplification of FGFR1 has been the most widespread criteria for the inclusion of lung cancer patients in clinical trials with FGFR inhibitors. Despite the initially described prevalence of this disorder in about 20% of squamous cell carcinomas, in practice, only 5-10% of these patients present this disorder, reducing the number of patients to be included in clinical trials with these inhibitors. . In addition, this criterion has been widely criticized due to the poor results obtained in these trials, with a very low percentage of partial responses. The results described in the present invention show that, although a tumor has amplification and / or high expression of FGFR1 and / or FGFR4, if it does not have high expression of N-cadherin, it will not respond to FGFR inhibitors. In this way, determining the expression of N-cadherin in patients with high expression of FGFR1 and / or FGFR4 will define the group of patients that will benefit from a therapy with FGFR inhibitors, which will avoid treating unnecessarily patients who will not respond to treatment, identifying the group of patients who will respond to the therapy and who, with the current criteria of patient selection (amplification of FGFR1) are not candidates for treatment.
    [0102]
    [0103] Definitions:
    [0104]
    [0105] Biomarker : Any biological parameter that allows to objectively measure the presence of a biological activity. For example, it allows to determine if a pharmacological treatment is going to be effective or to evaluate tolerance to a medication.
    [0106]
    [0107] Lung cancer : Set of diseases resulting from the malignant growth of cells of the respiratory tract, particularly lung tissue. Lung cancer usually originates from epithelial cells, and can lead to metastasis and infiltration to other tissues of the body. The types of lung cancer are divided into two types:
    [0108] - Small cell or small cell carcinomas: corresponds approximately to 20% of lung cancers. They are located preferably in the central zone of the lungs, being able to compress vessels or organs located in that level. They are characterized by their high aggressiveness and rapid growth.
    [0109] - Non-small cell carcinomas (NSCLC): represent the remaining 80% of lung cancers. The most frequent types are:
    [0110] a) Squamous or epidermoid carcinoma: It is the most frequent variety of bronchopulmonary cancer in Spain, representing 40% of non-small cell carcinomas.
    [0111] b) Adenocarcinoma: It represents 30% of non-small cell carcinomas. It is the least related to the consumption of snuff, but even so, it is more frequent in smokers.
    [0112] c) Large cell carcinoma: It is named for the size of the cells that make it up. It is the least frequent type of bronchopulmonary carcinomas, representing 10% of them.
    [0113]
    [0114] Expression (or level of expression): For the purposes of the present invention, expression is understood as the presence, detectable by standard techniques known in the state of the art, of a protein or a messenger RNA.
    [0115]
    [0116] High expression: For the purposes of the present invention, high expression is understood as the presence, detectable by standard techniques known in the state of the art, of a protein or a messenger RNA, above a reference value, compared to a reference sample, or with respect to the median of a reference population. For it to be considered that there is high expression of a biomarker, it must be at least 2 times higher than the expression of said marker in the reference sample.
    [0117]
    [0118] Reference sample : For the purposes of the present invention, it is considered that the reference sample with which the amount of protein or messenger RNA of a biomarker analyzed is compared is that which has low or no expression of said biomarker. In the present invention, but without limiting the scope of the invention, the reference sample of a determined biomarker consists of the arithmetic average of the quantification of the expression of said biomarker in at least three cell lines previously described in the state of art because they do not express this biomarker, or because they do it at a level that has no effect on the cell. The reference sample can also be obtained from samples from one or more individuals that have non-small cell lung cancer and do not respond to treatment with FGFR inhibitors, can be cell lines, "pool" of cells, can be obtained commercially, of a biobank of tissues or blood, of clinical studies published for a cohort of individuals, or of reference samples recognized in the sector such as those of the TCGA cohort (The Cancer Genome Atlas of the National Cancer Institute and National Human Genome Research Institute). In this case, instead of the arithmetic mean, the median would be used.The level of expression of a biomarker of the invention in the reference sample is considered a "reference value".
    [0119]
    [0120] Overexpression : For the purposes of the present invention, overexpression is understood to be the expression of a gene induced in a cell line by transfection with a plasmid expressing the gene of interest. Overexpression can be determined as an increase in the mRNA that encodes a given protein or an increase in the amount of protein.
    [0121]
    [0122] Activation of a receptor : For the purposes of the present invention, it is understood that a receptor is activated when it is capable of exerting its tyrosine kinase activity, triggering the specific cellular signaling cascades. Activation occurs under physiological conditions when a ligand or agonist binds to the receptor. Conditions such as mutations in the receptor, or the overexpression of it, but not limited to these, can lead to constitutive activation independent of ligand, which results in the activation of cellular signaling cascades downstream of the receptor, increasing the effect of the routes in the cell. The constitutive activation of receptors is related to the appearance of diseases. The inhibitors of a receptor diminish or eliminate their activation so they are commonly used as drugs in the treatment of diseases. Activating mutations have been described in the FGFR1 and FGFR4 genes that could be involved in the tumorigenesis of lung cancer. However, it has been proven that patients who carry such mutations do not necessarily respond to a treatment with FGFR inhibitors.
    [0123]
    [0124] For purposes of the present invention, the terms "anti-FGFR" and "FGFR inhibitor" are considered equivalent by targeting therapies whose effect is to decrease or eliminate the activation of FGFR receptors.
    [0125]
    [0126] For the purposes of the present invention, the terms "individuals" and "subjects" are considered synonymous and refer to any animal living being. In a preferred embodiment, the "individuals" or "subjects" in the present invention refer to human beings.
    [0127]
    [0128] In one embodiment, the present document describes an in vitro method for predicting the response of a subject suffering from lung cancer to a treatment with at least one FGFR inhibitor, comprising:
    [0129] a) detecting in a biological sample obtained from said subject the expression of the biomarker N-cadherin and also the expression of at least one of the biomarkers FGFR-1 and / or FGFR-4,
    [0130] b) compare the level of expression of the biomarkers determined in (a) with a reference sample,
    [0131] c) administering at least one FGFR inhibitor to the subjects having expression of the detected biomarkers in excess of the expression of the same biomarkers in the reference sample.
    [0132]
    [0133] In a more preferred embodiment, the level of expression of the biomarkers N-cadherin and FGFR1 and / or FGFR4 is determined by measuring the amount of protein in each of them, or by measuring the amount of mRNA of the genes encoding said proteins respectively. the sample. In a more preferred embodiment, the sequences of the biomarkers can be found in public access databases, with which an average expert in the field is familiar. By way of example, and without limiting the scope of this invention, the sequence of the N-cadherin protein, also known as Cadherin-2, corresponds to the code P19022 (UniProtKB) or Reference Sequence NCBI NP_001783.2 ( National Center for Biotechnology Information, US National Library of Medicine). By way of example, and without thereby limiting the invention, the sequence of the messenger RNA of N-cadherin corresponds to the reference sequence of NCBI NM_001792.4, the sequence SEQ ID NO: 1, or any which has a degree of identity with them of at least 80%, preferably at least 85%, more preferably at least 90%, 95%, 96%, 97%, 98% or 99% with respect to said sequence. By way of example, and without limiting the scope of the present invention, the sequence of the FGFR1 protein corresponds to the code P11362 of UniProtKB or the Reference Sequence NCBI NP_075598.2. By way of example, and without thereby limiting the invention, the sequence of the messenger RNA of FGFR1 corresponds to the reference sequence of NCBI NM_023110.2, the sequence SEQ ID NO: 2, or any that has a degree of identity with at least 80%, preferably at least 85%, more preferably at least 90%, 95%, 96%, 97%, 98% or 99% relative to said sequence. By way of example, and without limiting the scope of the present invention, the sequence of the FGFR4 protein corresponds to the code P22455 of UniProtKB or to the reference sequence NCBI NP_002002.3. By way of example, and without limiting the invention, the sequence of the messenger RNA of FGFR4 corresponds to the reference sequence of NCBI NM_002011.3, the sequence SEQ ID NO: 3 or any that has a degree of identity with them of at least 80%, preferably at least 85%, more preferably at least 90%, 95%, 96%, 97%, 98% or 99% with respect to said sequence. The degree of identity between two sequences can be determined by conventional methods, such as, for example, BLAST (Altschul SF 1999).
    [0134]
    [0135] In one embodiment of the invention, lung cancer is a non-small cell lung carcinoma. In a more preferred embodiment, the non-small cell lung carcinoma is selected from adenocarcinoma and squamous or squamous cell carcinoma.
    [0136]
    [0137] In one embodiment of the invention, the analyzed sample is selected from whole blood, plasma, serum, urine, sputum, sweat, bronchoalveolar lavage, biopsy of primary or metastatic tumor tissue. In a still more preferred embodiment, the biological sample is a biopsy of the primary tumor of the subject. For the purposes of the present invention, whole blood is defined as that which contains all its components, i.e., blood plasma and all formed elements (red blood cells, white blood cells and platelets). Plasma is defined as the liquid component of the blood, without the cellular fraction. The serum is defined as the fluid obtained after blood coagulation and clot elimination. It differs from plasma in the absence of coagulation factors. Urine is a yellow liquid discharge which is secreted by the kidneys as a result of purification and filtering of the blood; It accumulates in the bladder and is expelled through the urethra. Sputum is the discharge from the nose, throat or bronchi that is spit at once through the mouth in a sputum. Sweat is the transparent liquid that the sweat glands expel from the skin of mammals and that is expelled through the pores. Bronchoalveolar lavage (BAL) is defined as the instillation and subsequent aspiration of fluid in one or more lung segments or subsegments. It is estimated that with the realization of the LBA a sample of about one million alveoli (1% of the pulmonary surface) is taken, obtaining approximately 1 ml of real pulmonary secretions in the total of the recovered fluid. The biopsy is a piece of tissue or a part of organic liquid that is extracted from a living being, for diagnostic or prognostic purposes. The biopsy of primary tumor tissue is a biopsy of the tumor in the place where the cancer originates, in this case the lung. Biopsy of metastatic tumor tissue refers to a lymph node biopsy obtained by needle or puncture-aspiration of a sample of tissue from a nodule in a ganglion, or a biopsy of the tumor in a part of the body other than that originally a cancer formed
    [0138] The sample can be used fresh (directly obtained from the subject), cryopreserved, or fixed in formalin or preserved in paraffin.
    [0139]
    [0140] In one embodiment of the invention, the detection of the biomarkers can be done with any method that reflects their presence, such as the detection of the biomarker in its protein form or the detection of the messenger RNA encoding said protein (or fragments thereof). Methods for the detection of this type of molecules are widely known in the state of the art. By way of example, but not thereby limiting the scope of the present invention, the detection of biomarkers can be carried out by any of the following methods: HPLC (high performance liquid chromatography), LC / MS (liquid chromatography coupled to spectrometry mass, ELISA, DAS ELISA (sandwich ELISA with double antibody), protein immunoprecipitation, immunoelectrophoresis, Western Blot, protein immunostaining, Northern Blot, reverse transcription PCR (RT-PCR), quantitative PCR (q-PCR), RIA (radioimmunoassay), in situ hybridization or nuclease protection assay, immunocytochemical or immunohistochemical techniques or any "big data" technique (mass analysis of data based on biochips or microarrays) such as genomic DNA microarrays, protein microarrays, messenger RNA microarrays, cDNA microarrays, peptide microarrays, tissue microarrays, cellular or transfection microarrays, mic antibody roarrays, lysate or serum microarrays, reverse phase protein microarrays, peptide microarrays, genotyping microarrays, among others. In a more preferred embodiment, the detection of the messenger RNA of the biomarkers is performed by reverse transcription PCR (RT-PCR) or quantitative PCR (q-PCR). In a embodiment of the invention, it is considered that a biomarker is highly expressed in a sample and serves to predict the response of the subject to treatment, if the level of biomarkers detected in the sample is at least twice the level of the same marker in a reference sample. In a more preferred embodiment, the expression of the biomarker must be at least 5 times higher than that of the reference sample. In a still more preferred embodiment, the expression of the biomarker must be at least 10 times higher than that of the reference sample.
    [0141]
    [0142] In one embodiment of the invention, the subject suffering from lung cancer is a human being.
    [0143]
    [0144] In another embodiment of the invention, the FGFR inhibitor used in the treatment of lung cancer is selected from the group comprising, without thereby limiting the scope of the invention: BGJ398, AZD4547, Debio-1347, Dovitinib, BLU9931, FIIN- 2, JNJ-42756493, LY2874455, Ponatinib, BIBF1120, PD173074, PD166866, BLU554, S49076, NSC12, PHA-739358, TSU-68, BMS-540215, TKI-258, MK-2461, BMS-582664, AG 1296, SSR128129E , LY2874455 and SU5402.
    [0145]
    [0146] The present invention also describes the combination of the biomarker N-cadherin and at least one second biomarker selected from FGFR1 and / or FGFR4 for use in predicting the response of a subject suffering from lung cancer to treatment with FGFR inhibitors. In a particular embodiment, the level of expression the biomarkers are selected between the level of mRNA and / or the protein level of N-cadherin and FGFR1 and / or FGFR4.
    [0147]
    [0148] In a preferred embodiment of the above use, lung cancer is selected from adenocarcinoma and squamous or squamous cell carcinoma.
    [0149]
    [0150] In one embodiment of the above use, the FGFR inhibitors are selected from the group comprising, without thereby limiting the scope of the invention: BGJ398, AZD4547, Debio-1347, Dovitinib, BLU9931, FIIN-2, JNJ-42756493, LY2874455 , Ponatinib, BIBF1120, PD173074, PD166866, BLU554, S49076, NSC12, PHA-739358, TSU-68, BMS-540215, TKI-258, MK-2461, BMS-582664, AG 1296, SSR128129E, LY2874455 and SU5402.
    [0151]
    [0152] The present invention also discloses a method for predicting whether a subject suffering from lung cancer will respond to a treatment with FGFR inhibitors comprising the use of the N-cadherin biomarker, and in addition the use of at least one of the FGFR1 biomarkers and / or FGFR4.
    [0153] In a more preferred embodiment of the above prediction method, the expression levels of the biomarker N-cadherin and in addition at least one other biomarker selected from FGFR1 and / or FGFR4 is indicative that the subject is responder to the treatment.
    [0154]
    [0155] In a preferred embodiment, the present invention relates to a kit for predicting and / or predicting the response of a subject suffering from lung cancer to a treatment with FGFR inhibitors comprising:
    [0156] (a) means for detecting in a biological sample obtained from the subject the expression of the biomarker N-cadherin, on the one hand, and the expression of at least one of the biomarkers FGFR-1 and / or FGFR-4 by another,
    [0157] (b) means for comparing the level of expression of the biomarkers determined in (a) with a reference sample,
    [0158] (c) instructions for a medical professional to administer treatment with FGFR inhibitors only to those subjects that show high expression of N-cadherin and also high expression of FGFR1 and / or FGFR4.
    [0159]
    [0160] In a preferred embodiment of kit, the means for detecting expression of the biomarkers are selected from the group comprising antibodies to detect specific proteins or probes to detect the messenger RNA of N-cadherin and FGFR1 and / or FGFR4 and reagents to carry out detection, such as, for example, probes and primers that specifically recognize said messenger RNA. In one embodiment, the probes for the detection of the messenger RNA of the genes CDH2, FGFR1 and / or FGFR4 are selected from any sequence that hybridizes specifically with the RNA of these genes. By way of example, specific TaqMan assays, such as those described in Table 1 (Thermo Fisher) can be used. In a preferred embodiment, the kit comprises primers for PCR amplification of at least part of the messenger RNA sequence encoding the N-cadherin protein and further primers for PCR amplification of at least part of the messenger RNA sequences encoding the FGFR1 proteins and / or FGFR4. The sequences of the biomarkers of the invention (messenger RNA and protein) are known in the state of the art and any average expert could design primers, probes and antibodies for their detection.
    [0161]
    [0162] In another embodiment of the invention, referred to the kit, the antibodies used for the detection of the N-cadherin, FGFR1 and FGFR4 proteins are selected from any monoclonal or polyclonal antibody that specifically recognizes these proteins. By way of example, the antibodies that recognize the biomarkers are those that are described in Table 2 of the present report. In a preferred embodiment, the kit comprises monoclonal or polyclonal antibodies that specifically recognize the N-cadherin protein and also monoclonal or polyclonal antibodies that specifically recognize the FGFR1 and / or proteins. FGFR4. Said antibodies may or may not be labeled with radioactive isotopes, enzymes, fluorophores, chemiluminescent reagents, enzymatic substrates or cofactors, enzymatic inhibitors, particles, dyes, etc.
    [0163]
    [0164] In an embodiment of the invention referred to the kit, the means for comparing the level of expression of the determined biomarkers with a reference sample is carried out by means of the quantification of the expression levels of the biomarkers previously detected in the biological sample and in the reference sample. The expression levels can be quantified by any conventional method of the state of the art. By way of illustration, but not by limiting the invention, the levels of the biomarkers can be quantified, for example, by means of specific quantification programs coupled to the detection systems previously indicated.
    [0165]
    [0166] In an embodiment of the invention referred to the kit, instructions for a medical professional to administer treatment with FGFR inhibitors refer to a document or computer program which, from a table of values and / or data processing , indicate from them, if said treatment should be administered to a specific patient, whose biological sample analyzed in said kit, has provided the aforementioned values and / or data.
    [0167]
    [0168] In another embodiment, the present invention relates to a device for diagnosing and / or predicting the response of a subject suffering from lung cancer to a treatment with FGFR inhibitors, comprising the elements necessary to analyze:
    [0169] a) the expression level of N-cadherin and
    [0170] b) the level of expression of FGFR1 and / or FGFR4
    [0171] in a biological sample obtained from the subject suffering from lung cancer.
    [0172]
    [0173] In a preferred embodiment the kit or device of the invention can contain oligonucleotides designed from a known sequence or an mRNA and / or capable of hybridizing with the sequence of the CDH2 gene , and in addition the FGFR1 and / or FGFR4 genes for the subsequent PCR amplification.
    [0174]
    [0175] Preferably, the kit or device of the invention comprises at least:
    [0176] a) an anti-N-cadherin antibody and
    [0177] b) an anti-FGFR1 antibody and / or an anti-FGFR4 antibody
    [0178]
    [0179] In a preferred embodiment of said kit or device, the antibody recognizes the human protein and can be humanized or non-humanized, produced in mouse, or in rabbit or in any other species or synthetic. In another more preferred embodiment, the antibody is monoclonal. In another more preferred embodiment, the antibody is labeled with a fluorochrome. More preferably, the fluorochrome is selected from the list comprising Fluorescein (FITC), Tetramethylrhodamine and derivatives, Phycoerythrin (PE), PerCP, Cy5, Texas, allophycocyanin, or any combination thereof.
    [0180]
    [0181] More preferably, the kit and the device of the present invention comprise the means necessary to compare the level of expression detected with a reference sample.
    [0182] The kit can also include, without any type of limitation, buffers, agents to prevent contamination, inhibitors of protein degradation, etc. On the other hand, the kit can include all the supports and containers necessary for its start-up and optimization. Preferably, the kit further comprises instructions for carrying out any of the methods described above.
    [0183]
    [0184] In another embodiment, the present invention describes a method of treating a subject suffering from lung cancer comprising:
    [0185] (a) determining the presence of the biomarker N-cadherin in a biological sample obtained from said subject,
    [0186] (b) determining the presence of at least one of the biomarkers FGFR1 and / or FGFR4 in the same sample,
    [0187] (c) administering a therapeutically effective amount of the FGFR inhibitor if the subject has high expression of the N-cadherin biomarker and also has high expression of at least one of the biomarkers FGFR1 and / or FGFR4, when compared to a reference sample,
    [0188] wherein the determination of the presence of the biomarkers in steps (a) and (b) can be performed simultaneously or sequentially.
    [0189]
    [0190] In another embodiment, the present invention relates to an in vitro method for diagnosing and / or predicting the response of a subject suffering from lung cancer to a treatment with FGFR inhibitors comprising determining, in a sample of the subject, the expression of the N-cadherin biomarker and also to determine the expression of at least one of the biomarkers FGFR1 and / or FGFR4, compare said expression with a reference sample, in which the high expression of N-cadherin and in addition the high expression of FGFR1 and / or FGFR4 is indicative that the subject suffering from lung cancer will respond to treatment.
    [0191] In another embodiment, the present invention relates to the use of the biomarkers N-cadherin, FGFR1 and FGFR4 to predict whether a subject suffering from lung cancer will respond to a treatment with FGFR inhibitors.
    [0192] Another aspect of the invention relates to a storage medium readable by a computer comprising program instructions capable of causing a computer to perform the steps of any of the methods of the invention.
    [0193]
    [0194] Another aspect of the invention relates to a transmissible signal comprising program instructions capable of causing a computer to perform the steps of any of the methods of the invention.
    [0195]
    [0196] Unless defined otherwise, all the technical and scientific terms used herein have the same meaning as those customarily understood by a person skilled in the field of the invention. Methods and materials similar or equivalent to those described herein can be used in the practice of the present invention. Throughout the description and claims the word "comprises" and its variants, are not limiting and therefore do not intend to exclude other technical characteristics, additives, components or steps. The term "comprises" also includes the term "consists".
    [0197]
    [0198] The present invention demonstrates for the first time that the pro-oncogenic function of the FGFR1 and FGFR4 genes in lung cancer depends on the expression of the N-cadherin protein. In the absence of this, both genes generally present a tumor suppressor role. A high expression of FGFR1 in models of xenografts derived from lung cancer patients shows that the efficacy of a selective FGFR inhibitor is only observable in patients with high expression of N-cadherin. In all of the above embodiments of the invention or group of related inventions, "high expression of N-cadherin", "high expression of FGFR1" and "high expression of FGFR4" should be interpreted to mean that said expression is, at least 2 times higher than the expression of the same biomarkers in a reference sample.
    [0199]
    [0200] EXAMPLES
    [0201]
    [0202] Materials and methods
    [0203]
    [0204] Analysis of gene expression
    [0205]
    [0206] RNA extraction
    [0207]
    [0208] For the extraction of the RNA from the cell lines, the Trizol reagent (Life Technologies) was used, following the manufacturer's instructions. Subsequently, the RNA was precipitated with isopropanol, washed with 75% ethanol and resuspended in DEPC water (water treated with diethylpyrocarbonate).
    [0209] For the extraction of total RNA from tissue fixed with formalin and preserved in paraffin, the sheets of tumor tissue were dewaxed by the use of Xylol. Total RNA was extracted using the RecoverAll extraction kit (Life Technologies), using the manufacturer's instructions for the extraction of RNA from biological tissue.
    [0210]
    [0211] Once the RNA was extracted, its concentration was quantified by means of the NanoDrop equipment (ThermoScientific) and stored at -80 ° C for later use.
    [0212]
    [0213] Retrotranscription of RNA
    [0214]
    [0215] RNA samples were retrotranscribed using the TaqMan Reverse Transcription retrotranscription kit (Life Technologies), following the manufacturer's instructions. In each reaction, 1000 ng of RNA was used in 10 j L, with 10 jL of master mix, in a final volume of 20 j L. The reactions were subjected to the thermocycling protocol 10 minutes at 25 ° C, 120 minutes at 37 ° C and 5 minutes at 85 ° C.
    [0216]
    [0217] DNA preamplification
    [0218]
    [0219] The RNA extracted from the waxed tissue was pre-amplified using the TaqMan Preamp Master Mix kit (Applied Biosystems), following the manufacturer's instructions. The final volume of the amplification reaction was 10 jL and we added 100 ng of total cDNA per reaction. We used the 14 cycle preamp protocol described in the manufacturer's instructions (10 minutes at 95 ° C, 14 cycles of: 15 seconds at 95 ° C and 4 minutes at 60 ° C). After pre-amplification, the samples were diluted 1:20 prior to carrying out the quantitative PCR.
    [0220]
    [0221] Quantitative PCR in real time
    [0222]
    [0223] Each real-time PCR reaction was performed in triplicate, according to the protocol indicated by the manufacturer for the Taqman probes (ThermoFisher) and the TaqMan master mix for qPCR (ThermoFisher). The final volume of each reaction was 10 μL , which contained 5 μL of the master mix, 2.5 μL of the TaqMan probe of the gene under study and 2.5 μL of the cDNA sample. The concentration of the cDNA samples was 25 ng / jL in the case of the non-pre-amplified samples. In pre-amplified samples, 2.5 | j L of the 1:20 dilution of the pre-amplification reaction. In addition, a negative control without a cDNA sample was carried for each probe to rule out contamination in the water, in the master mix or in the probe. A thermocycling protocol of 40 cycles was followed (10 minutes at 95 ° C, 40 cycles of: 15 seconds at 95 ° C and 1 minute at 60 ° C).
    [0224]
    [0225] The relative quantification of mRNA expression is determined from the Ct values obtained in the reaction, defining Ct as the number of the cycle in which signal is detected of amplification of the target gene above a predetermined threshold, which allows to distinguish between a signal of real amplification and noise. For each sample, the average of three technical replicates for each gene was calculated, and this mean value of Ct was normalized with the Ct of the endogenous load control gene (glyceraldehyde-3-phosphate dehydrogenase, GAPDH, for cell line extracts and Beta -2-microglubine, B2M, for tumor extracts), obtaining the ACt value. Expression levels were represented in the 2-ACt form which is more intuitive because higher values of 2-ACt indicate higher expression of the gene.
    [0226]
    [0227] In the case of the determination of mRNA expression in extracts from cell lines, the mean and standard deviation of the 2-ACt values from three independent biological replicates were calculated. The assays used in preamplification and in the determination of mRNA expression are described in Table 1.
    [0228]
    [0229] Table 1. Tests used for the determination of the mRNA expression of the genes of interest.
    [0230]
    [0231] Target gene Supplier Reference
    [0232] FGFR1 Hs00917379_m1 Life technologies
    [0233] FGFR4 Hs01106908_m1 Life technologies
    [0234] N-cadherin Hs00983056_m1 Life technologies
    [0235] E-cadherin Hs01023894_m1 Life technologies
    [0236] B2M Hs99999907_m1 Life technologies
    [0237] GAPDH Hs99999905_m1 Life technologies
    [0238]
    [0239] Protein analysis
    [0240]
    [0241] To determine the protein expression of the samples, first, the total proteins were extracted. The cells of the cell lines were washed with PBS twice and lysis buffer (RIPA (Sigma), supplemented with a cocktail of protease inhibitors (using Mini EDTA-free, Roche) and a cocktail of phosphatase inhibitors (PhosSTOP) was added. EASYpack, Roche) at the concentration recommended by the manufacturer Cell lysates were collected by scraping, on ice, and added to a tube.The cell debris was removed by centrifugation at 15,000 xg for 10 minutes at 4 ° C and the supernatant (Protein extract) was stored in aliquots at -80 ° C. Quantification of protein extracts was performed using the modified Bradford method (BioRad), according to the manufacturer's instructions, using as a control known concentrations of serum albumin (BSA).
    [0242]
    [0243] The total proteins of the tumors from xenografts were obtained by adding the lysis buffer on the previously pulverized tissue fragment in a pre-prepared mortar. cooled with liquid nitrogen to prevent thawing of the fragment, incubated on ice for 2 hours, shaking every 10 minutes, and the volume was collected in 2ml tubes that were centrifuged at 15,000 xg for 10 minutes at 4 ° C to remove the debris of undissolved tissue and the supernatant was stored at -80 ° C. The extraction buffer and the quantification method used were the same as in the case of protein extraction of cell lines.
    [0244]
    [0245] Western blot
    [0246]
    [0247] 5X loading buffer (62.5 mM Tris-HCl pH 6.8, 10% glycerol, SDS 1%, 2-mercaptoethanol 5%, bromophenol blue 0.0025% (Sigma)) was added to the samples and denatured. for 5 minutes at 95 ° C. Then it was loaded in the electrophoresis gel to perform the western blot, or stored at -20 ° C.
    [0248]
    [0249] Protein immunodetection was performed according to a standard protocol on PDVF membranes (GE Healthcare). The proteins were separated in SDS polyacrylamide gels using a 1X Tris HCl 0.13 M electrophoresis buffer, 0.95 M glycine, 0.5% SDS and transferred to PDVF membranes using a Trans-Blot Turbo kit (BioRad ). The transfer was performed at 400 mA for 3 hours in transfer buffer (0.025 M TrisHCl, 0.2 M glycine, 20% methanol). The membranes were blocked for 1 hour under stirring with the blocking buffer (TBS, 0.1% Tween20 and 1% BSA). Subsequently, the membranes were incubated with the appropriate dilution of primary antibody for 16 hours at 4 ° C. After this incubation, the membranes were washed with washing buffer (TBS 0.1% Tween-20) and incubated with a 1: 5,000 dilution of the appropriate peroxidase-conjugated secondary antibody, for one hour at room temperature. The detection was performed by means of a chemiluminescent reaction (Clarity ECL, Biorad) and visualization by means of a luminescence detection equipment (ChemiDoc, BioRad).
    [0250]
    [0251] The antibodies used in the assays described herein are indicated in Table 2.
    [0252]
    [0253] To quantify the bands detected in the western blot assays, the software included in the chemiluminescence detection equipment (ImageLab, BioRad) was used. The volume of the band of the protein of interest was quantified and this was normalized with the volume of the band corresponding to the gene of constitutive expression, which served as a load control (alpha tubulin, also called tubulin).
    [0254]
    [0255] The reference value of a biomarker in a reference sample is calculated from the value of the quantification of its expression in three cell lines that do not express or have an expression level that has no effect on the cell. The values of this quantification are normalized as indicated above and the arithmetic mean of the expression is calculated normalized biomarker in the three cell lines. In the case of the biomarkers FGFR1 and FGFR4, the expression of the reference sample was calculated from the cell lines H2009, H358 and H1650. In the case of N-cadherin, the reference sample was calculated from the expression of the biomarker in cell lines A459, H460 and H2009.
    [0256]
    [0257] Table 2 : Antibodies used to determine protein expression of proteins of interest
    [0258]
    [0259] Type Diluc. Diluc Target protein Mol. Weight. Ref. Provider
    [0260] Western blot antibody immunofl FGFR1 Mon. rabbit 150 kDa 9740 CST 1: 1000 1: 100 FGFR4 Mon. rabbit 100 kDa 8562 CST 1: 1000 1: 100 pFGFRI Pol. rabbit 150 kDa 06-1433 Millipore 1: 2000 - (Tyr653 / 654)
    [0261] pFGFR4 (Tyr642) Pol. rabbit 100 KDa MBS856043 MyBiosource 1: 2000 -AKT Pol. rabbit 60 KDa 9272 CST 1: 1000 -pAKT (Ser473) Pol. rabbit 60 KDa 9271 CST 1: 1000 -p42 / p44 (ERK1 / 2) Pol. Rabbit 42/44 kDa 9102 CST 1: 1000 -p-p42 / p44 Pol. Rabbit 42/44 kDa 9101 CST 1: 1000
    [0262] (ERK1 / 2)
    [0263] (Thr202 / Tyr204)
    [0264] STAT3 Mon. mouse 80 kDa 9139 CST 1: 1000 -pSTAT3 (Tyr705) Pol. rabbit 80 kDa 9145 CST 1: 1000 -N-cadherin Mon. rabbit 135 kDa 13116 CST 1: 1000
    [0265] N-cadherin 135 kDa ThermoFisher 1: 100 E-cadherin Mon. rabbit 125 kDa 3195 CST 1: 1000 -a-Tubulina Mon. 55 kDa mouse T9206 Sigma 1: 5000 -Sec. anti-rabbit Pol. goat 7074 CST 1: 5000 - (HRP)
    [0266] Secondary anti Pol. Horse 7076 CST 1: 5000 -ratón (HRP)
    [0267] Sec. Anti-rabbit Pol. Goat R37116 ThermoFisher - 1: 250 (Alexa Fluor 488)
    [0268] Sec. Anti-mouse Pol. Donkey A-31570 ThermoFisher - 1: 250 (Alexa Fluor 555)
    [0269] Mon = monoclonal antibody. Pol = polyclonal antibody. Mol weight = molecular weight. Ref = reference. Diluc = Dilution. Immunofl = immunofluorescence. HRP = horseradish peroxidase.
    [0270]
    [0271] Cell biology
    [0272]
    [0273] A panel of cell lines containing two immortalized lung cell lines, four lung epidermoid carcinoma lines and thirteen adenocarcinoma lines, whose characteristics are shown in Table 3, was used.
    [0274] Table 3: Lung cell lines
    [0275]
    [0276] Line Type Conduction mutation
    [0277] Ref. Histological cell culture medium described
    [0278] A549 ADC KRAS p.G12S Helfrich 2006 DMEM supplemented with sodium pyruvate, HEPES and non-essential amino acids
    [0279] H460 ADC KRAS p.Q61H Helfrich 2006 RPMI 1640
    [0280] H2009 ADC KRAS p.G12A COSMIC RPMI 1640
    [0281] H358 ADC KRAS p.G12C Helfrich 2006 RPMI 1640
    [0282] H1650 ADC EGFR E746-E750 of the 2009 White RPMI 1640
    [0283] H1975 ADC EGFR L858R / T790M COSMIC RPMI 1640
    [0284] HCC827 ADC EGFR E746-E750 from Helfrich 2006 RPMI 1640
    [0285] H3122 ADC Translocation EML4-ALK COSMIC RPMI 1640
    [0286] v1
    [0287] H2228 ADC Translocation EML4-ALK COSMIC RPMI 1640
    [0288] v3
    [0289] H1781 ADC
    [0290] H1437 ADC
    [0291] Calu-3 ADC TN Helfrich 2006 DMEM
    [0292] Calu-1 ESC KRAS p.G12C COSMIC McCoy's 5a
    [0293] HTB59 ESC KRAS p-G12V COSMIC McCoy's 5a
    [0294] H520 ESC TN COSMIC, RPMI 1640
    [0295] Helfrich 2006
    [0296] H226 ESC TN COSMIC, RPMI 1640
    [0297] Helfrich 2006
    [0298] NL20 I TN COSMIC F12 supplemented following the indications
    [0299]
    [0300]
    [0301]
    [0302] ADC = Adenocarcinoma, ESC = Squamous cell carcinoma, TN = Triple negative (nomenclature referring to cell lines without alterations in KRAS, EGFR or ALK), I = Immortalized
    [0303] Cultivation of cell lines
    [0304]
    [0305] The cell lines were cultured following the indications of the ATCC, with the exception of A549, also supplementing all the media with 40u / mL of penicillin (Sigma), 40 ^ g / mL of steptomycin (Sigma) and 1 ^ g / mL of amphotericin B (Sigma), and with glutamine (Sigma) in the case of media that did not include stable glutamine in its composition. A549 was cultured in DMEM medium supplemented with 0.01M HEPES (Sigma), 1mM sodium pyruvate (Sigma) and 1X non-essential amino acids (Sigma), in addition to the supplements described above. Cells were grown in 10 cm plates and subcultured 1: 4 every 2-3 days by trypsin treatment. The manipulation of the cell lines was carried out in a laminar flow cabin of type N-Bio-NA (biosafety level 2) and its culture was carried out in incubators (ThermoScientific, Series 8000 Water-Jacketed CO 2 Incubators) at 95% of relative humidity and 5% CO 2 .
    [0306]
    [0307] Assays in which cell lines were stimulated with fetal bovine serum (FBS) were sown and upon reaching 60-70% confluence they were incubated for 5 hours with medium without FBS. Then, on the one hand, protein extracts corresponding to the basal state were obtained, and on the other hand the stimulation was carried out with 10% SFB. The cells were stimulated for 15 minutes and protein extraction proceeded (explained above).
    [0308]
    [0309] Cell transfection
    [0310]
    [0311] The cell lines were transfected with the plasmids described in Table 4. For this, TransIT-X2 transfection reagent (Mirus) was used, following the manufacturer's instructions. 24 hours before transfection the cells were seeded in 6-well plates, looking for approximately 40% confluency in each well for the day of transfection. Before transfection, the medium was changed to the cells by adding 2.5 mL of medium. Next, the transfection particles were added to the DNA and the cells were incubated with them for 72 hours. After this time, the cells were transferred to 10 cm plates and, once they were adhered to the plate (after about 24 hours), fresh medium was added with the selection antibiotic at the appropriate concentration. As a negative control of the transfection, a plate with the untransfected cell line also exposed to the selection medium was used. During the process of selection of the transfected cells (3 or 4 weeks), the antibiotic culture medium was renewed 3 times per week. After this period, it was found that in the negative control no cell survived. The generated colonies were trypsinized and reseeded in a new plate, establishing a pool of the different transfected clones, with which a stable transfected cell line was constituted. In the generated line, over-expression or silencing was confirmed according to the examples described below and was cryopreserved. During the cultivation of the generated lines, it was maintained in the presence of selection antibiotic at half the concentration of the one used during the selection. In each transfection the appropriate antibiotic was used according to the transfected plasmid at the appropriate concentration according to the cell line (Table 5): puromycin (Calbiochem), blasticidin (Sigma) or G418 (Santa Cruz). In the case of transfections with plasmids with a reporter gene (GFP) the cells were amplified and then the transfected ones were separated by means of a cell separator by flow cytometry using the BD LSRFortessa (BD) equipment.
    [0312] In the case of transfections of RNAs of interference ("short hairpin shRNAs", shRNAs), two stable cell lines were generated with silencing of the expression of the gene of interest, using in each a different shRNA, in order to ensure that the The effects observed were not derived from the nonspecific silencing of the expression of a different gene Transfection was carried out using the plasmids pRS (puromycin) or pB-RS (blastomycin) according to Table 4.
    [0313]
    [0314] In the case of co-transfections of more than one plasmid in the same cell line, the transfections were performed independently and subsequently. The selection antibiotics of the transfected plasmids were maintained in the medium at the maintenance concentration to maintain a selective pressure, combining two or three antibiotics. The only time that the selection antibiotics were not present was during the incubation period of the cells with the transfection reagent (72 hours), since these could interfere with the transfection, decreasing its efficiency.
    [0315]
    [0316] Table 4. Plasmids used in the tests
    [0317]
    [0318] Name Vector Ref. Method Vendor Use Selection
    [0319] pCMV6 pCMV6 G418 PS100001 Origene Control overexpression of FGFR1 and FGFR4
    [0320] pCMV6-FGFR1 pCMV6 G418 RC202080 Origene Overexpression of FGFR1 pCMV6-FGFR4 pCMV6 G418 RG204230 Origene Overexpression of FGFR4 pRS scramble pRS Puromycin TR20003 Origene Control of silencing of shRNA FGFR1 and FGFR4
    [0321] pRS-shRNA-FGR1 pRS Puromycin TR320354 Origene Silencing by shRNA of FGFR1
    [0322] pRS-shRNA-pRS Puromycin TR320356 Origene Silencing by shRNA of FGFR4 FGFR4
    [0323] PL-SIN-PGK-EGFP PL-SIN-PGK GFP # 21316 Addgene Control of overexpression of N-cadherin
    [0324] pCCL-c-MNDU3c- pCCL-c- GFP # 38153 Addgene Overexpression of N-PGK-EGFP-N-MNDU3c-PG cadherin
    [0325] cadherin
    [0326] pB-RS pB-RS Blasticidin TR30024 Origene Silencing control of N-cadherin and E-cadherin pB-RS shRNA N- pB-RS Blasticidin HC138304 Origene Silencing of N-cadherin cadherin
    [0327] pB-RS shRNA E- pB-RS Blasticidin HC138277 Origene Silencing of E-cadherin cadherin
    [0328]
    [0329] The control vectors correspond to the empty vectors.
    [0330] Table 5: Concentrations of antibiotics used.
    [0331]
    [0332] Cell line G418 Puromycin Blasticidin
    [0333] A549 2 ug / mL
    [0334] H460 2 mg / mL
    [0335] H2009 1 mg / mL 3 ug / mL
    [0336] H1650 1 mg / mL
    [0337] H1975 1 mg / mL
    [0338] HCC827 1 mg / mL
    [0339] H3122 2 mg / mL 3 ug / mL
    [0340] Calu-3 2 ug / mL
    [0341] Calu-1 1 mg / mL
    [0342] H520 2 ug / mL 2 ug / mL
    [0343] H226 1 mg / mL
    [0344] NL20 1 mg / mL 1 ug / mL 2 ug / mL
    [0345]
    [0346] Tumorigenicity assays
    [0347]
    [0348] The tumorigenicity tests were repeated a minimum of three times in order to confirm the results. In addition, within each repetition of the experiment, each condition was seeded in triplicate.
    [0349]
    [0350] a) Growth curve
    [0351]
    [0352] 3,500 cells were seeded per well in 12-well plates. At 24 hours (day 0) the cells of the first point of the curve were fixed, and every 24-48 hours a new point of the curve was fixed and the medium was changed to the rest. The fixed plates were preserved with the cells in PBS at 4 ° C until all points of the curve were fixed. The plates were then stained with crystal violet for 20 minutes, the plates were washed and allowed to dry. Once dry, 20% acetic acid was added to each well to dilute the violet crystal and the absorbance at 595 nm was measured on a VICTOR optical reading device (PerkinElmer). All absorbances were normalized with respect to the absorbance of day 0 of each experimental condition. Finally, this normalized value (growth relative to day 0 on the Y axis) was plotted against time (days, X axis).
    [0353]
    [0354] b) Clonability test
    [0355]
    [0356] A number of cells of between 1,000 and 5,000 cells was seeded, according to the cell line, in 10 cm plates. The medium was renewed once a week for 2 or 3 weeks depending on the cell line. After this time, the cells were fixed with a solution of glutaraldehyde in 0.5% PBS for 20-30 minutes and stained with a 1% crystal violet solution in water. After washing and drying the plates, the number of colonies was quantified.
    [0357] c) Anchor free growth ( Soft agar assay)
    [0358]
    [0359] 100,000 cells / well were resuspended in medium with 0.35% agarose, which was seeded on a medium base with 0.7% agarose previously solidified in 6-well plates. After 24 hours, 3 mL of complete medium was added to each well, which was renewed twice a week. After one or two months, depending on the line under test, photos of the colonies were taken by means of a microscope (# IX2-SLP, Olympus) with integrated camera (# U-CMAD3, Olympus). In these photos, the number of colonies was quantified and their size was determined. The result is represented in a graph showing the relative number of colonies (with respect to time 0) of the cells that overexpress or inhibit the expression of a gene compared with the control cells, transfected with the empty vector. It was determined if the difference in the relative number of colonies with respect to the control is statistically significant (* p-values less than 0.05, ** p-values less than 0.01, and *** p-values less than 0.001) .
    [0360]
    [0361] Co-immunolocalization
    [0362]
    [0363] The cells were seeded on sterile coverslips and fixed with a 4% paraformaldehyde solution in PBS for 15 minutes. After two washes with PBS, the cells are waterproofed with a 0.1% solution of Triton X-100 in PBS for 5 minutes. They are then incubated for one hour in blocking solution (PBS, 0.1% Triton X-100, 1% SAB) at room temperature. Subsequently, they are incubated with the appropriate dilution in blocking solution of primary antibody, for 3 hours at room temperature. After three washes with 0.1% Triton X-100 PBS of 5 minutes duration and under agitation, the cells were incubated with the secondary antibody at the appropriate dilution, in blocking solution, for 1 hour at room temperature. In a confocal microscope (SP5-WLL), photos of at least 20 cells per experimental condition are taken in the different replicas of the experiment to analyze the co-localization of the proteins under study.
    [0364]
    [0365] Co-Immunoprecipitation of membrane proteins
    [0366]
    [0367] Total proteins were extracted as described above, but using a 50 mM HEPES extraction buffer, 150 mM NaCl and 1% n-octylglucoside, supplemented with a cocktail of protease inhibitors (c) Mini EDTA-free, Roche) and phosphatases (PhosSTOP EASYpack, Roche). The total protein concentration of the extracts was quantified as previously indicated and aliquots of 2 mg were prepared. In these aliquots, protein pre-clearance was performed by incubation with 10 | j L resin EZ View Red Protein G Affinity Gel (Sigma), which was used as an immunoprecipitation substrate for 2 hours at 4 ° C under gentle agitation. Next, the resin was removed by centrifugation at 6000 g at 4 ° C for 1 minute. In parallel to the pre-clearance, the resin was conjugated with the primary antibody against the protein to immunoprecipitate (anti-N-cadherin, described in Table 2), incubating 10 jL of resin with 2 jg of antibody for each mg of protein in the sample in 3% lysis buffer of bovine serum albumin (BSA), for 2 hours under gentle agitation at 4 ° C. As a negative control of the immunoprecipitation, an aliquot of the protein sample incubated with particles conjugated to an unspecific antibody of the same isotype was used as the antibody against the protein of interest, at the same concentration as this one. Then, three washes of the resin conjugated with the antibody were performed with lysis buffer, centrifuging between washes 1 minute at 6000 g at 4 ° C to remove the used buffer and add new one. Subsequently, the resin conjugated with the antibody was incubated with the sample for 16 hours under gentle agitation at 4 ° C. Then, 5 washes of the resin were carried out with the immunoprecipitate, resuspending it in lysis buffer and then centrifuging for 1 minute at 6000 g at 4 ° C. The supernatant was discarded, were added 20 to 30 j L of lysis buffer and loading buffer was added 5X, as indicated above. The samples were boiled 5 minutes at 95 ° C and centrifuged at 12,000 g for 3 minutes. The supernatant was used to perform a western blot, as described above, with the aim of detecting with specific antibodies anti-N-cadherin, anti-FGFR1 and anti-FGFR4 the presence of the biomarkers in each stage of the immunoprecipitation. In this way, it is detected if there are biomarkers that co-immunoprecipitate with N-cadherin, indicating a binding in the cell membrane. As controls of the immunoprecipitation, two aliquots of the protein extract were preserved, one before and one after the immunoprecipitation.
    [0368]
    [0369] Animal experimentation techniques
    [0370]
    [0371] All the procedures performed with animals were approved by the Animal Protection Committee of the Autonomous Community of Madrid (PROEX134 / 16).
    [0372]
    [0373] a) Xenografts with cell lines in immunosuppressed mice
    [0374]
    [0375] The cells of the cell line were counted to xenograft and prepared at a final concentration of 2 million cells in 100 | j L of PBS. Next, Matrigel solution (BD, # 356234) was added to the cell suspension, at a ratio of 1: 1, and 200 subcutaneously injected.
    [0376] j L on both flanks of immunodepressed nude mice of 5-6 weeks of age, under anesthesia by inhalation of isoflurane.
    [0377]
    [0378] b) Xenografts of tumors derived from patients ( PDXs)
    [0379] Tumors, from patients with non-small cell lung cancer, are implanted covered with Matrigel (BD, # 356234) on the flank of immunodepressed nude mice of 5-6 weeks of age, under anesthesia by inhalation of isuofuorane and under analgesia by buprenorphine . To perform the implant, a small cut is made in the flank of the mouse under anesthesia and analgesia and the tumor fragment is introduced, about 100-150 mm3 in volume.
    [0380] c) Determination of tumor growth of xenografts
    [0381]
    [0382] The size of the tumors generated by the xenografts was measured weekly by a measuring gauge. The shortest and longest length of each tumor was measured and the tumor volume was calculated with the formula: 0.5 x (longest dimension) x (shortest dimension) 2.
    [0383]
    [0384] The mean of the normalized tumor volumes was plotted against time. This was calculated by normalizing the tumor volume of each measurement to the first measurement made (7 days after implantation). The mean error was calculated with the formula: standard deviation / Vñ, where n is the number of tumors in each group.
    [0385]
    [0386] Once the tumors reached 1000 mm3 in volume, the mice were sacrificed and the tumors removed. The tumor samples were sliced and frozen rapidly in cryotubes, for storage at -80 ° C and subsequent extraction of RNA or protein.
    [0387]
    [0388] d) Treatments of PDXs
    [0389]
    [0390] The selective inhibitor of FGFR AZD4547 was tested to check its effect on the growth of tumors (PDXs). For this, the model of interest was implanted in 4-6 mice per treatment group to be performed as indicated above and the growth of the generated tumors was monitored. When reaching a volume of between 100 and 150 mm3, the mice were distributed in the different treatment groups, including in each group those whose tumor size has a mean and similar standard deviation, and leaving a control group treated with the vehicle, as reference. After the establishment of the groups, treatments were started, lasting between 3 and 5 weeks, depending on the growth rate of each model and the drug or drugs used.
    [0391]
    [0392] The concentration of AZD4547 used was 7.5 mg / kg / day administered from Monday to Friday. The route of administration of the drug was oral. At the end of the treatment, the mice were sacrificed and the tumors processed and stored as indicated above.
    [0393] The growth of the tumors is shown by graphs of tumor growth versus time, where each measurement of the tumor volume is relativized to the initial one after beginning the treatment, and the mean and the mean error for each treatment group is represented. The variation of tumor volume is represented by bar graphs, which show the increase (or decrease), expressed as a percentage, of the volume of each tumor with respect to the initial volume, in each treatment group.
    [0394]
    [0395] Statistic analysis
    [0396]
    [0397] Statistical analyzes were performed using the statistical software package SPSS (IBM), using the statistical tests detailed below to obtain the p-values. Those below 0.05 were considered statistically significant, and these values were plotted as * for p-values <0.05, ** for p-values <0.01 and *** for values <0.001.
    [0398]
    [0399] a) Analysis of in vitro and in vivo experiments
    [0400]
    [0401] To analyze if the differences found between the different conditions tested in the in vitro experiments are statistically significant, the nonparametric Mann-Whitney U test was performed, in the values corresponding to the independent biological replicates of the experiments.
    [0402]
    [0403] In order to analyze if the growth differences of the tumors of the different experimental conditions in the in vivo tests reached statistical significance, the same test was performed in the values corresponding to the normalized values of the tumor sizes.
    [0404]
    [0405] b) Analysis of clinical cohorts
    [0406]
    [0407] Regarding the clinical data, the Kaplan Meier method was used for the analysis of survival, using the Log-Rank model and the Cox model of proportional risks to adjust the explanatory variables and obtain the p-values. Overall survival was defined as the time period between diagnosis and the last clinical review or death, and progression-free survival was defined as the time period between the initial diagnosis and the diagnosis of recurrence.
    [0408]
    [0409] Example 1. Effect of the expression of the FGFR1 and FGFR4 genes in tumorigenesis in squamous cell carcinoma of the lung
    [0410] To test the effect of FGFR1 and FGFR4 on lung cancer, the effect of overexpression and silencing of these genes in different lung cancer cell lines was analyzed.
    [0411]
    [0412] First, the endogenous expression of FGFR1 and FGFR4 was analyzed in the 18 different cell lines described in Table 3. 16 cell lines are from non-small cell lung cancer coming from the two most representative histologies of this pathology, adenocarcinoma and squamous carcinoma or epidermoid. Cell lines were selected with the different molecular alterations of greater therapeutic relevance in lung cancer (mutation in KRAS, mutation in EGFR, translocation EML4-ALK, or lines without any of the mentioned alterations, which we will call "triple negative"), and two immortalized lung cell lines.
    [0413]
    [0414] The expression of FGFR1 and FGFR4 at the protein level was determined. To do this, the total proteins were extracted from the cell lines, denatured and the presence of FGFR1 and FGFR4 was detected by western blot using the anti-FGFRI and anti-FGFR4 monoclonal antibodies described in Table 2. Tubulin was used as charge control .
    [0415]
    [0416] As seen in Figure 1, the protein expression of FGFR1 in adenocarcinoma cell lines (ADC) is low compared to squamous cell carcinoma (ESC) lines. The protein expression of FGFR4 is less frequent and is not representative of any of the histological types under study.
    [0417]
    [0418] Next, the bands detected in the western blot assay were quantified as described in the materials and methods herein. As a reference sample for evaluating the expression of FGFR1 and FGFR4, the average expression of these receptors normalized with tubulin was used in cell lines H2009, H358 and H1650. In the case of N-cadherin, the reference sample was the average of biomarker expression normalized with tubulin in cell lines A459, H460 and H2009.
    [0419] Table 6 Quantification of the expression of biomarkers in reference samples
    [0420] Normalized expression Deviation Cell line value
    [0421] with tubulin standard reference
    [0422] H358 0.22 0.11 0.557
    [0423]
    [0424] H358 0.17 0.09 0.163
    [0425]
    [0426]
    [0427] N-cadherin H460 0.22 0.14 1.25
    [0428]
    [0429]
    [0430] To determine the role of FGFR4 in the epidermoid carcinoma cell lines, the epidermoid carcinoma cell lines H226 (Triple negative) and Calu-1 (mutated KRAS) were selected to overexpress the FGFR4 gene in them. Overexpression of the FGFR4 gene was carried out by transfecting the cell lines with the plasmid pCMV6-FGFR4 described in Table 4. Next, the cells were cultured and the tumorigenic characteristics of the samples were analyzed by growth curves, soft agar assays and analysis of the expression of pro-oncogenic signaling pathways.
    [0431]
    [0432] Figure 2 shows the relative growth of lung epidermoid carcinoma cell lines H226 (upper part) and Calu-1 (lower part) over time. It is observed how the samples that overexpress FGFR4 have higher cell growth ( Figure 2A) , clonability ( Figure 2B ) and ability to generate free-anchored growth colonies ( Figure 2C ) than the control lines (transfected with the empty vector (EV)) . Overexpression of this gene induces its own overactivation, in addition to that of different pro-oncogenic signaling pathways, as demonstrated by the expression of the proteins pSTAT3, pAKT and p-p42 / p44 ( Figure 2D ). All tests were performed at least in triplicate. Representative growth curves are shown. For the clonability and the anchor free growth test, the mean and standard deviation of the replication colonies are shown, after having been normalized to the control condition, which takes the value of 1. For the anchor free growth test , the mean and standard deviation of the size of the colonies is also shown. The p-values were obtained by Student's T test with a 95% confidence interval and are represented as * p-values less than 0.05, such as ** p-values less than 0.01, and as *** the p-values less than 0.001.
    [0433] In order to delve into the pro-oncogenic effect of FGFR1 and FGFR4 on the tumorigenic properties of epidermoid carcinoma cell lines, the expression of FGFR1 and FGFR4 was silenced independently in a line with high endogenous expression of both genes, the H520 ( Figure 1 ). The silencing of the genes was carried out as described in the Materials and methods present in this report, using the vector pRNA scramble shRNA as a control, and the vectors pRS-shRNA-FGFR1 and pRS-shRNA-FGFR4 for the silencing of the FGFR1 and FGFR4 genes respectively.
    [0434]
    [0435] Figure 3A shows the relative growth of the H520 line with the silenced FGFR1 gene (upper part) and with the silenced FGFR4 gene (lower part) over time in medium with 10% SFB. It is observed that the growth of the cell lines with some of the silenced FGFRs is lower than the control cells. This effect is especially pronounced in the case of the silencing of FGFR4. In the free anchor growth ( Figure 3C ) and clonability ( Figure 3B ) assays, a lower tumorigenic capacity of the lines with some of the silenced FGFRs is also observed, in comparison with the control line. Regarding the activation of oncogenic signaling pathways under study, it was observed that the silencing of either of the two genes produces a decrease in the activation of the silenced FGFR receptor, as well as of the STAT3, AKT and p42 / p44 pathways ( Figure 3D ) Samples (a) and (b) of the experiments in Figure 3 correspond to two independent shRNAs for silencing the same gene, in order to avoid that the observed effect is derived from nonspecifically silencing a different gene. All tests were performed at least in triplicate. Representative growth curves are shown. For the clonability and the anchor free growth test, the mean and standard deviation of the replication colonies are shown, after having been normalized to the control condition, which takes the value of 1. For the anchor free growth test , the mean and standard deviation of the size of the colonies is also shown. The p-values were obtained by Student's T test with a 95% confidence interval and are represented as * p-values less than 0.05, such as ** p-values less than 0.01, and as *** the p-values less than 0.001.
    [0436] These data confirm the oncogenic role described for FGFR1 in squamous cell carcinoma of the lung and suggest a similar role for FGFR4 in this pathology, something that has not been demonstrated so far. The data presented indicate that the expression of FGFR4 and / or FGFR1 in squamous cell carcinoma cell lines produces an increase in the tumorigenic characteristics of the samples, as well as the activation of the pro-oncogenic signaling pathways.
    [0437] Example 2. Effect of expression of FGFR1 and FGFR4 genes on tumorigenesis in lung adenocarcinoma
    [0438]
    [0439] In order to verify the effect of FGFR1 and FGFR4 on the oncogenic properties of lung adenocarcinoma cell lines, cell lines with different tumorigenic molecular alterations were selected, in order to check if their effect is dependent on the molecular context. To do this, cell lines with relevant alterations in adenocarcinoma and with low expression of both receptors were selected to be able to express them independently.
    [0440]
    [0441] The procedure was the same as that described in Example 1. The cell lines H2009 (with mutation in KRAS) and H3122 (carrier of the translocation EML4-ALK) were selected and the recipients were overexpressed in each of them. independently transfecting the lines with the appropriate plasmid according to Table 4.
    [0442]
    [0443] Surprisingly, and contrary to what occurs in squamous cell carcinoma of the lung, overexpression of each of the receptors caused a decrease in the tumorigenic characteristics of the two samples, as observed in the cell proliferation assays ( Figure 4A ) , clonability ( Figure 4B ) and anchor free growth test ( Figure 4C ), with respect to their respective control lines transfected with the empty vector (EV).
    [0444]
    [0445] Next, the activation of several pro-oncogenic signaling pathways related to FGFR was measured ( Figure 4D ). A lower activation of STAT3 and AKT was observed under the conditions of overexpression of FGFR1. All tests were carried out in triplicate. Representative growth curves are shown. For the clonability and the anchor free growth test, the mean and standard deviation of the replicas are shown, after having been normalized to the control condition, which takes the value of 1. For the anchor free growth test, it is shown also the mean and standard deviation of the size of the colonies. EV = empty vector, FGFR1 = overexpression of FGFR1, SFB = fetal bovine serum. The p-values are represented by asterisks (*, p <0.05; **, p <0.01; ***, p <0.001).
    [0446]
    [0447] It should be noted that overexpression of FGFR1 or FGFR4 in these lines does not induce overactivation of the overexpressed receptor as in the case of epidermoid lines (See Figure 3D Vs Figure 4D).
    [0448]
    [0449] One of the adenocarcinoma lines, A549 with KRAS mutation, expresses high levels of FGFR1 and FGFR4. To check the effect of both genes on the tumorigenic characteristics of this line, both FGFRs were silenced individually using RNA from interference (shRNA). The nomenclature of the shRNAs (a) and (b) correspond to two independent shRNAs to silence the same gene, in order to avoid that the observed effect is derived from nonspecifically silencing a different gene. All tests were carried out in triplicate. Representative growth curves are shown. For the clonability and the anchor free growth test, the mean and standard deviation of the replicas are shown, after having been normalized to the control condition, which takes the value of 1. For the anchor free growth test, it is shown also the mean and standard deviation of the size of the colonies. Control = nonspecific shRNA, shFGFR1 = silencing of FGFR1, shFGFR4 = silencing of FGFR4, SFB = Fetal bovine serum. The p-values are represented by asterisks (*, p <0.05; **, p <0.01; ***, p <0.001).
    [0450]
    [0451] In agreement with the results obtained previously, the silencing of the expression of either of the two genes causes an increase in cell proliferation ( Figure 5A ), an increase in the generation of colonies in the anchor free growth test and in the size of these colonies with respect to the control line ( Figure 5C ). In the cloning tests, however, no differences were observed in the number of colonies generated in any of the cases ( Figure 5B ). When the activation of STAT3 and AKT was measured, greater activation of these routes was observed under silencing conditions of FGFR1 or FGFR4 with respect to the control line and the same occurs in the case of p42 / p44, although with an increase in their less marked activation ( Figure 5D ).
    [0452]
    [0453] All these results together suggest a tumor suppressive role of both FGFRs in pulmonary adenocarcinoma and an oncogenic role in squamous carcinoma.
    [0454]
    [0455] Example 3. Identification of N-cadherin as responsible for the different behavior of FGFR1 and FGFR4 in lung adenocarcinoma and squamous carcinoma
    [0456]
    [0457] In order to explain the differential effect of FGFR1 and FGFR4 on the tumorigenesis of non-small cell lung cancer identified in Examples 1 and 2, candidate genes that could be responsible for this behavior were looked for.
    [0458]
    [0459] For this, it was verified if the mesenchymal or epithelial characteristics of the cell lines could determine the role of the different FGFR in lung cancer. To do this, we analyzed the expression of N-cadherin (mesenchymal marker) and E-cadherin (epithelial marker) (Gheldof 2013) in the collection of lung cancer cell lines described in Figure 1.
    [0460] Figure 6 shows how both proteins are differentially expressed in the two histological types analyzed (adenocarcinoma, ADC and squamous or squamous cell carcinoma, ESC). E-cadherin is expressed in almost all of the adenocarcinoma lines, but in none of squamous cell carcinoma, while N-cadherin shows the opposite result.
    [0461]
    [0462] To check whether N-cadherin is responsible for the pro-tumorigenic effects of FGFR1 and FGFR4, N-cadherin was overexpressed in two adenocarcinoma lines (H2009 and H3122) by transfecting them with the N-cadherin overexpression plasmid (Table 4) in combination or not with overexpression plasmids of FGFR1 or FGFR4.
    [0463]
    [0464] As shown in Example 2, overexpression of these FGFRs has a tumor suppressive effect. However, when N-cadherin and each of the receptors (CDH2-FGFR1 or CDH2-FGFR4) are overexpressed, both FGFRs not only fail to exert a tumor suppressor effect, but exert a pro-oncogenic effect, increasing the oncogenic characteristics of both lines, above the control lines and of the cells overexpressing only N-cadherin, as observed in Figures 7A-7C (10% growth curves of SFB (7A), clonability (7B) and free anchor growth (7C)). All tests were carried out in triplicate. Representative growth curves are shown. For the clonability and the anchor free growth test, the mean and standard deviation of the replicas are shown, after having been normalized to the control condition, which takes the value of 1. For the anchor free growth test, it is shown also the mean and standard deviation of the size of the colonies. EV1 = empty vector 1, EV2 = empty vector 2, CDH2 = Overexpression of N-cadherin, FGFR1 = Overexpression of FGFR1, FGFR4 = Overexpression of FGFR4, SFB = Fetal bovine serum. The p-values are represented by asterisks (*, p <0.05; **, p <0.01; ***, p <0.001). Furthermore, when studying the activation of the pro-oncogenic signaling pathways in these lines, a decrease in the activation of the pro-oncogenic signaling pathways is observed when either of the two FGFRs is overexpressed in the absence of N-cadherin, with respect to to control, and the opposite effect when FGFRs are co-overexpressed with N-cadherin ( Figure 7D ).
    [0465]
    [0466] From this experiment it is deduced that the expression of N-cadherin is responsible for the oncogenic effect of FGFR1 and FGFR4, which would explain the differences in the behavior of both genes between adenocarcinoma and squamous cell carcinoma.
    [0467]
    [0468] Next, the opposite experiment was performed on an immortalized lung cell line with high endogenous expression of N-cadherin (NL20), but without endogenous expression of FGFR1 or FGFR4 (Figure 1). In this experiment, N-cadherin was silenced, as described above, and combined with the overexpression of each FGFR (shCDH2-FGFR1 or shCDH2-FGFR4). Figures 8A and Figure 8B show the result of the tumorigenicity tests on the growth curves and the soft agar assay, respectively. The results indicate that expression of FGFR1 or FGFR4 has a tumor suppressive effect in the absence or presence of low levels of N-cadherin, (shCDH2-EV1-FGFR1 and shCDH2-EV1-FGFR4), and a pro-tumorigenic effect in the presence of high expression of N-cadherin (EV1-EV2-FGFR1 and EV1-EV2-FGFR4).
    [0469]
    [0470] Figure 8C shows the study of the activation of oncogenic signaling pathways. The results obtained were concordant, showing an increase of the tumorigenicity and of the activation of the routes under study when any of the FGFRs is overexpressed in the presence of endogenous N-cadherin, and the opposite effect when the FGFRs are overexpressed in the presence of reduced levels of N-cadherin.
    [0471]
    [0472] From this experiment it is deduced that the tumorigenic effect of FGFR1 and FGFR4 in non-small cell lung cancer (NSCLC) is the expression of N-cadherin.
    [0473]
    [0474] In addition, to check the observed effects, they are reproduced in vivo, xenografts of the aforementioned cell lines were made in nude immunodepressed mice and the growth of the tumors generated from the xenografts was determined.
    [0475]
    [0476] Figure 8D shows that the growth of the tumors generated by the different lines correlates with the results obtained in vitro, observing that the tumors co-expressing N-cadherin and FGFR1 or FGFR4 have a significantly higher growth than those that only express N-cadherin , or that do not express any of the genes, while tumors that only express FGFR1 or FGFR4 show a slower tumor growth, as demonstrated in the previous examples.
    [0477] All these data confirm that the responsible for the tumorigenic effect of FGFR1 and FGFR4 in non-small cell lung cancer is the co-expression of N-cadherin with either of these two genes.
    [0478]
    [0479] Finally, to study whether the tumorigenic effect of the combination of N-cadherin and FGFR1 or FGFR4 may be due to a physical interaction between the proteins, co-immunofluorescence experiments were performed to check whether the proteins co-localize in the membrane the cell.
    [0480]
    [0481] For this, the cell line NL20 was used, which has an endogenous expression of N-cadherin, with exogenous overexpression of FGFR1 or FGFR4. Figure 9A shows that there is partial colocalization of N-cadherin with FGFR1 and FGFR4, in some regions of the cell membrane. These results suggest that the interaction between proteins could be physical. To verify this hypothesis, co-immunoprecipitation experiments were performed.
    [0482] A cell line with high endogenous expression of the three proteins (H520) was selected. The immunoprecipitation of N-cadherin was performed, and the presence of FGFR1 or FGFR4 in the immunoprecipitate was determined, as described in the materials and methods herein.
    [0483]
    [0484] Figure 9B shows that both FGFR1 and FGFR4 co-immunoprecipitate with N-cadherin, which supports the existence of a physical interaction between both types of receptors.
    [0485]
    [0486] Example 4. Function of N-cadherin in the prognostic role of FGFR1 and FGFR4 in patients with non-small cell lung cancer
    [0487]
    [0488] To verify the importance of N-cadherin in the prognostic role of FGFR1 and FGFR4 in patients with non-small cell lung cancer and to validate the previous results, two study cohorts were used: a discovery cohort and a validation cohort.
    [0489]
    [0490] A discovery cohort of 109 patients diagnosed with non-small cell lung cancer (NSCLC) in early stage (I-III) and treated with radical surgery, from the Virgen del Rocío University Hospital (Seville) (NSCLC n = 109 ) was used. Table 7 shows the characteristics of the cohort. The research project was evaluated and approved by the hospital ethics committee (2012PI / 241). The patients signed the mandatory informed consent of the hospital biobank. The whole project followed the universal ethical principles contained in the Declaration of Helsinki.
    [0491]
    [0492] The samples of tumor tissue included in paraffin were analyzed in all cases after the anatomopathological diagnosis was made. In these samples the mRNA was extracted as described above, although it is also possible to detect and quantify the expression of the genes of interest by means of immunohistochemistry directly in the biopsies. Overall survival (OS) and progression free survival (PFS) were analyzed, that is, the time elapsed during and after treatment in which the cancer does not grow or spread further, compared to time (months). The p-values were calculated by a Log Rank analysis.
    [0493]
    [0494] Figure 10A shows the Kaplan-Meier curves of survival according to gene expression in the study cohort. It is observed that the group with high expression of N-cadherin and FGFR1 has worse data of progression-free survival (PFS) and global OS), while the group with high expression of FGFR1 and low expression of N-cadherin shows the best data for both types of survival. It is noteworthy that in the group of low expression of N-cadherin and high of FGFR1, more than 70% of patients continue alive, contrasting with 30-40% in the other groups. Analogously, samples with low N-cadherin and high expression of FGFR4 have a better survival (both PFS and OS) than samples that have high expression of both genes.
    [0495]
    [0496] Table 7. Characteristics of our cohort of non-small cell lung cancer.
    [0497]
    [0498] Number of patients 109
    [0499]
    [0500] Sex
    [0501] Male 100 (92%)
    [0502] Female 9 (8%)
    [0503]
    [0504] Median age (years) 65.0 [54.0-78.0]
    [0505]
    [0506] Tabacco habit
    [0507] Smoker 56 (51.3%)
    [0508] Ex-smoker 48 (44.1%)
    [0509] Non-smoker 5 (4.6%)
    [0510]
    [0511] Squamous cell carcinoma 58 (53.2%)
    [0512] Stage I-II 43 (74.1%)
    [0513] Stage III 15 (25.9%)
    [0514]
    [0515] Adenocarcinoma 36 (33%)
    [0516] Stage I-II 30 (83.3%)
    [0517] Stage III 6 (16.6%)
    [0518]
    [0519] Other histologies 15 (13.7%)
    [0520]
    [0521] Figure 10B shows the survival curves of patients with high expression of FGFR1 and / or FGFR4 as a function of N-cadherin expression. As expected, patients with high expression of one or both of the FGFRs and low N-cadherin expression show a better progression-free survival and overall than the subset with high expression of both genes (hazard ratio 2.06 [1 , 01-4,23], p = 0.045 and hazard ratio 1.89 [1.02-3.49] p = 0.039, respectively) These survival curves clearly show the potential of N-cadherin as a modulator of paper of FGFR1 and FGFR4 in the oncogenesis of lung cancer.
    [0522]
    [0523] To validate the prognostic role of N-cadherin and FGFR1 or FGFR4, the same analyzes were performed in two publicly available clinical databases in The Cancer Genome Atlas (TCGA), one of patients with adenocarcinoma (N = 522) and another of carcinoma. epidermoid (N = 504) (Table 8) (http://cancergenome.nih.gov/).
    [0524] Table 8. Characteristics of the adenocarcinoma and epidermoid carcinoma cohorts of the TCGA.
    [0525]
    [0526] Histology Adenocarcinoma Squamous cell carcinoma
    [0527] Number of patients 522 504
    [0528]
    [0529] Sex
    [0530] Male 219 (37.9%) 314 (42.4%)
    [0531] Female 253 (43.8%) 108 (21.2%)
    [0532] Unknown 106 (18.3%) 83 (16.4%)
    [0533]
    [0534] Median age (years) 66.9 [59.6-73.4] 68.6 [62.3-73.8]
    [0535]
    [0536] Tabacco habit
    [0537] Smoker 111 (19.2%) 113 (22.2%)
    [0538] Ex-smoker 276 (47.8%) 284 (56.3%)
    [0539] Non-smoker 71 (12.3%) 17 (3.4%)
    [0540] Unknown 120 (20.7%) 91 (18.1%)
    [0541]
    [0542] Stadium
    [0543]
    [0544] 115 (24.4%) 124 (24.3%)
    [0545]
    [0546] 25 (4.3%) 6 (1.2%)
    [0547] Unknown 107 (18.5%) 86 (17.1%)
    [0548]
    [0549] The categorical variables are represented as the number of patients (percentage of the total) and the quantitative variables as the median [interquartile range].
    [0550]
    [0551] In these cohorts, the patients were divided according to the mRNA expression of FGFR1 and N-cadherin, or of FGFR4 and N-cadherin, and survival was analyzed. The cut-off point between high and low expression in the case of the cohort of adenocarcinoma patients was defined as the median, for the case of FGFR1 and FGFR4, and as the first quartile for the case of FGFR4. In the case of the squamous cell carcinoma cohort, the cut-off point was the median expression for each of the genes.
    [0552]
    [0553] Figure 11A shows the results of the reference cohort for adenocarcinoma. It is observed, in a similar way to the previous results, that patients who have high expression of FGFR1 and low expression of N-cadherin have a better survival prognosis compared to samples with high expression of N-cadherin and high expression of FGFR1 (Risk ratio of 2.38 [1.15 - 4.94], p = 0.016 for progression-free survival, and of 1.63 [0.90 - 2.95], p = 0.101 for overall survival Regarding FGFR4, similar results were obtained, with a risk ratio of 1.61 [1.01 - 2.59], p = 0.046 for progression-free survival and of 1.79 [1.06 - 2.51], p = 0.024 for overall survival.
    [0554]
    [0555] In addition, patients with high expression of one or both FGFRs were selected in the cohort and this subset of patients was divided according to the level of expression of N-cadherin. Figure 11B shows a clear trend in which, in this subset of patients, high levels of N-cadherin expression are associated with worse survival (hazard ratio of 1.46 [0.98 - 2.17], p = 0.059 for progression-free survival, and of 1.63 [1.11-2.38], p = 0.011 for overall survival, thus reproducing the results obtained in the discovery cohort.
    [0556]
    [0557] In the squamous cell carcinoma cohort the data were very similar for FGFR1, observing that in patients with high expression of FGFR1, those with high expression of N-cadherin present worse prognosis (risk ratio of 1.88 [1.25-2] , 79], p = 0.017 for progression-free survival, and of 1.34 [0.89 - 1.99], p = 0.087 for overall survival). However, in the case of FGFR4, there are no differences in prognosis in this cohort ( Figure 12A ), nor in having both receptors ( Figure 12B ). These data support the role of N-cadherin as modulator of the anti-or pro-oncogenic role of FGFR1 and FGFR4.
    [0558]
    [0559] From these results it is concluded that the expression of FGFR1, FGFR4 and N-cadherin is related to the prognosis in lung cancer. This, on the one hand, demonstrates the role of N-cadherin as responsible for the pro-oncogenic effect of FGFR1 and FGFR4, and also demonstrates the validity of the use of these genes as biomarkers of prognosis of the disease.
    [0560]
    [0561] Example 5. Relationship between the expression of N-cadherin, FGFR1 and FGFR4 and the use of FGFR inhibitors in the treatment of lung cancer
    [0562]
    [0563] The above results demonstrate the role of N-cadherin as responsible for the pro-oncogenic effect of FGFR1 and FGFR4. At present, FGFR inhibitory agents are being used in clinical trials as a therapeutic treatment for lung cancer. However, it is known that this type of treatment, in clinical trials, is not effective in all patients, which causes side effects in patients without remitting the disease, and the delay in the administration of a better treatment. To date, the reason for the lack of effectiveness of this type of drugs is unknown.
    [0564]
    [0565] From the results shown in the previous examples, it was decided to check whether the differences in the expression of N-cadherin and FGFR1 and / or FGFR4 and their relationship with the effects pro-tumorigenic in lung cancer cell lines, are also related to the activity of selective FGFR inhibitors described for the treatment of lung cancer.
    [0566]
    [0567] a) N-cadherin as a predictive factor of anti-FGFR therapy in vitro
    [0568]
    [0569] To check whether the expression of N-cadherin is decisive in determining the efficacy of the inhibition of FGFR in the treatment of lung cancer, the efficacy, in terms of inhibition of growth, of two selective FGFR inhibitors was tested. For this, cell lines with high endogenous expression of FGFR1 and / or FGFR4 were selected in addition and with low expression of N-cadherin (A549 and H460), or with high endogenous expression of FGFR1 and / or FGFR4 and high expression of N-cadherin (H520 and H226). In these lines, the effect on cell proliferation of two selective inhibitors of FGFR: BGJ398 and AZD4547 (SELLECKCHEM, Ref. S2183 and S2801 respectively) was analyzed as a function of time.
    [0570]
    [0571] The result of cell proliferation (relative growth as a function of time) of cell lines without treatment or treated with BGJ398 0.5 j M, BGJ3981 | jM, AZD45470.5 | jM or AZD45471 | jM is shown in Figure 13A . It is observed that both inhibitors reduce growth only in the lines with high expression of N-cadherin, but did not exert a significant effect in those lines with low or no expression of N-cadherin at the concentrations tested. These results support the predictive role of N-cadherin in relation to the inhibitory therapies of FGFR.
    [0572]
    [0573] Figure 13B shows the effect of two selective FGFR inhibitors on the proliferation of cell lines with exogenous expression of FGFR1 or FGFR4, in combination or not with exogenous overexpression of N-cadherin (CDH2). It is observed that the inhibitors have no effect on the growth of cell lines without expression of exogenous N-cadherin, but when it is expressed (lower row).
    [0574]
    [0575] b) N-cadherin as a predictive factor of anti-FGFR therapy in vivo
    [0576]
    [0577] To check if this predictive role is relevant in vivo, the efficacy of the inhibitor that showed better efficacy in in vitro experiments , AZD4547, was tested in different tumors derived from xenografted patients in immunosuppressed mice ( "Patientderived xenografts", PDXs, see materials and methods).
    [0578]
    [0579] Two models of adenocarcinoma with similar expression of FGFR1 were selected, one with high expression of N-cadherin (TP91) and another with low expression of this protein (TP60). We also selected two models of squamous cell carcinoma with comparable expression of FGFR1, with high and low expression of N-cadherin (TP114 and TP13, respectively).
    [0580] In addition, a model of squamous cell carcinoma with high expression of FGFR1, FGFR4 and N-cadherin (TP96) was selected ( Figure 14A ).
    [0581]
    [0582] Figure 14B shows how the treatment with AZD4547 produced no effect on the tumor growth of the models with low expression of N-cadherin (TP60 and TP13), regardless of their histology. However, in the tumor models with high expression of N-cadherin (TP91, TP114 and TP96, Figure 14C ) the treatment with this selective inhibitor of FGFR caused a considerable reduction in growth, with a median volume reduction of 14.4%, 25.5 % and 1.4% with respect to the control condition, respectively.
    [0583]
    [0584] It should be noted that the treatment with AZD4547 caused a complete tumor regression in 1/5, 2/5 and 2/5 of the treated tumors, respectively in each model. In the TP96 model, in addition, the partial response to treatment was reached, defined as a median reduction of tumor volume of 50% or more with respect to volume at the beginning of treatment ( Figure 14D ).
    [0585]
    [0586] When analyzing the effect of the inhibitor on the signaling pathways related to FGFR in two of the treated models (TP60 and TP91), we observed that the treatment does not alter the activation of the routes studied in the model with low expression of N-cadherin (TP60 ), whereas in the model with high expression of N-cadherin, TP91, AZD4547 caused a decrease in the levels of pSTAT3, pAKT and a modest reduction of activation p-p42 / p44 ( Figure 14E ). All these results support the predictive role of N-cadherin in therapy directed against FGFR, regardless of histology.
    [0587]
    [0588] These results show that the expression of these biomarker genes (N-cadherin in combination with FGFR1 and / or FGFR4) in a sample of lung cancer from a patient is indicative of the effectiveness of an anti-FGFR drug. By means of a simple analysis of the expression of the biomarkers N-cadherin and FGFR1 and / or FGFR4 it is possible to determine if an anti-FGFR drug is going to be efficient in the treatment of a subject. The results show that the effectiveness of the treatment depends on the expression of N-cadherin in combination with the expression of FGFR1 and / or FGFR4. It has not been described in the state of the art the analysis of the expression of N-cadherin to predict the response to a treatment with FGFR inhibitors, so it would not be obvious for a person skilled in the art to determine the expression of these specific biomarkers to know if a subject is going to be resistant or sensitive to treatment with drugs that inhibit FGFR.
    [0589]
    [0590] All the data presented in this report support the highly predictive role of the N-cadherin biomarker in anti-FGFR therapy for the treatment of tumors with high expression of FGFR1 and / or FGFR4.
    [0591] BIBLIOGRAPHY
    [0592]
    [0593] Altschul SF et al. Basic local alignment search tool. J Mol Biol (1990); 215 (3): 403-10.
    [0594]
    [0595] White R et al. A gene-alteration profile of human lung cancer cell lines. Human mutation (2009); 30: 1199-206.
    [0596]
    [0597] Dutt A et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PloS one 2011; 6 (6): e20351.
    [0598]
    [0599] Gheldof A and Berx G. Cadherins and epithelial-to-mesenchymal transition. Prog Mol Biol Transl Sci (2013); 116: 317-36.
    [0600]
    [0601] Helfrich BA, et al. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clinical cancer research: an official journal of the American Association for Cancer Research (2006); 12: 7117-25.
    [0602]
    [0603] Huang HP et al. The prognostic significance of fibroblast growth factor receptor 4 in non-smallcell lung cancer. OncoTargets and therapy (2015); 8: 1157-64.
    [0604]
    [0605] Jiang T et al. FGFR1 amplification in lung squamous cell carcinoma: a systematic review with meta-analysis. Lung Cancer 2015; 87 (1): 1-7.
    [0606]
    [0607] Lim SH et al. Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study. Cancer (2016); 122 (19): 3024-31.
    [0608]
    [0609] Nguyen T and Mége RM. N-cadherin and Fibroblast Growth Factor Receptors crosstalk in the control of developmental and cancer cell migrations. Eur J Cell Biol (2016); 95 (11): 415-26.
    [0610] Qian X et al. N-cadherin / FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem / progenitor cell-like properties. Oncogene (2014); 33 (26): 3411-21.
    [0611]
    [0612] Quintanal-Villalonga A et al. Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implcations. Disease markers 2016 1-14.
    [0613]
    [0614] Hanze J et al. Epithelial mesenchymal transition status is associated with anti-cancer responses to receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells. BMC Cancer (2013); 11 (13): 589.
    [0615]
    [0616] Wesche et al. Fibroblast growth factors and their receptors in cancer. Biochem J (2011); 437: 199-213.
    权利要求:
    Claims (20)
    [1]
    An in vitro method for predicting the response of a subject suffering from lung cancer to a treatment with at least one FGFR inhibitor, comprising:
    c) detect in a biological sample obtained from said subject the levels of the biomarker N-cadherin in combination with the expression of at least one of the biomarkers FGFR1 and / or FGFR4,
    d) comparing the level of expression of the biomarkers determined in (a) with a reference sample, in which high levels of the detected markers, is indicative that the subject will respond to the treatment.
    [2]
    2. The in vitro method according to claim 1, wherein the determination of the expression level of the biomarkers is carried out by measuring the amount of N-cadherin protein and the amount of FGFR1 and / or FGFR4 protein in the sample, or by measuring the amount of mRNA of the CDH2 gene and the amount of mRNA of the FGFR1 and / or FGFR4 genes in the sample.
    [3]
    3. In vitro method according to claim 1 or 2, wherein the lung cancer is non-small cell lung cancer.
    [4]
    4. The in vitro method according to claim 3, wherein the non-small cell lung cancer is selected from adenocarcinoma and squamous or squamous cell carcinoma.
    [5]
    In vitro method according to any of claims 1 to 4, wherein the biological sample analyzed in step a) is selected from the group comprising: whole blood, serum, plasma, sputum, sweat, urine, bronchoalveolar lavage , biopsy of primary or metastatic tumor tissue of the subject.
    [6]
    6. In vitro method according to claim 5, wherein the biological sample is a biopsy of primary tumor tissue of the subject.
    [7]
    7. In vitro method according to any of claims 1 to 6, wherein the detection of the amount of biomarkers is carried out by at least one of the methods selected from: HPLC (high performance liquid chromatography), LC / MS (liquid chromatography coupled to mass spectrometry, ELISA, DAS ELISA, protein immunoprecipitation, immunoelectrophoresis, Western Blot, protein immunostaining, Northern Blot, reverse transcription PCR (RT-PCR), quantitative PCR (q-PCR), RIA (radioimmunoassay), in situ hybridization , nuclease protection assay, mass sequencing, immunocytochemical or immunohistochemical techniques microarray of genomic DNA, protein microarray, messenger RNA microarray, cDNA microarray, peptide microarray, tissue microarray, cell or transfection microarray, antibody microarray, lysate or serum microarray, reverse phase protein microarray, microarray of genotyping peptides or microarrays.
    [8]
    8. In vitro method according to any of claims 1 to 7, wherein high levels of the detected biomarkers correspond to a level at least two times higher than the level of the same marker in a reference sample.
    [9]
    9. Method according to any of claims 1 to 8, wherein the at least one FGFR inhibitor is selected from the group comprising BGJ398, AZD4547, Debio-1347, Dovitinib, BLU9931, FIIN-2, JNJ- 42756493, LY2874455, Ponatinib, BIBF1120, PD173074, PD166866, BLU554, S49076, NSC12, PHA-739358,
    TSU-68, BMS-540215, TKI-258, MK-2461, BMS-582664, AG 1296, SSR128129E,
    LY2874455 and SU5402.
    [10]
    10. Combination of the biomarkers N-cadherin and at least one second biomarker selected from FGFR1 and FGFR4, for use in the prognosis and / or prediction of the response of a subject suffering from lung cancer to treatment with FGFR inhibitors.
    [11]
    11. Combination of biomarkers for use according to claim 10, wherein the level of expression of each biomarker is determined by measuring the mRNA level of the CDH2 and FGFR1 and / or FGFR4 genes , and / or the protein level of N-cadherin and FGFR1 and / or FGFR4.
    [12]
    12. Combination of biomarkers for use, according to any of claims 10 or 11, wherein the lung cancer is a non-small cell carcinoma selected from adenocarcinoma or squamous cell carcinoma.
    [13]
    13. Combination of biomarkers for use according to any of claims 10 to 12, in the at least one FGFR inhibitor is selected from the group comprising BGJ398, AZD4547, Debio-1347, Dovitinib, BLU9931, FIIN-2, JNJ-42756493, LY2874455, Ponatinib, BIBF1120, PD173074, PD166866, BLU554, S49076, NSC12, PHA-739358, TSU-68, BMS-540215, TKI-258, MK-2461, BMS-582664, AG 1296, SSR128129E, LY2874455 and SU5402.
    [14]
    14. Kit for predicting and / or predicting the response of a subject suffering from lung cancer to a treatment with FGFR inhibitors comprising:
    (d) means for detecting in a biological sample obtained from the subject the levels of the biomarker N-cadherin, on the one hand, and the expression of at least one of the biomarkers FGFR1 and / or FGFR4 by another,
    (e) means for comparing the level of expression of the biomarkers determined in (a) with a reference sample,
    (f) instructions for a medical professional to administer treatment with FGFR inhibitors only to those subjects that show high expression of N-cadherin and also high expression of FGFR1 and / or FGFR4.
    [15]
    15. Kit according to claim 14, wherein the determination of biomarker levels is performed by measuring the amount of biomarker protein N-cadherin and the amount of protein from at least one of the biomarkers FGFR1 or FGFR4 in the shows, or by measuring the amount of mRNA of the CDH2 gene and the amount of mRNA of at least one of the FGFR1 or FGFR4 genes in the sample.
    [16]
    16. Kit according to claim 14 or 15, wherein the lung cancer is non-small cell lung cancer.
    [17]
    17. Kit according to claim 16, wherein the non-small cell lung cancer is selected from adenocarcinoma and squamous or squamous cell carcinoma.
    [18]
    18. Kit according to any of claims 14 to 17, wherein the means for detecting the levels of the biomarkers comprise antibodies that specifically recognize the N-cadherin proteins and antibodies that specifically recognize the FGFR1 and / or FGFR4 proteins, or primers and / or probes that specifically detect the presence of mRNA of the CDH2 gene and in addition primers and / or probes that specifically detect the presence of the mRNA of the FGFR1 and / or FGFR4 genes .
    [19]
    19. Kit according to claims 14 to 18, wherein the biological sample is selected from the group comprising: whole blood, serum, plasma, sputum, sweat, urine, bronchoalveolar lavage, biopsy of primary or metastatic tumor tissue.
    [20]
    20. Kit according to any of claims 14 to 19, wherein the detection of the biomarkers is carried out by at least one of the methods selected from: HPLC (high performance liquid chromatography), LC / MS (liquid chromatography coupled mass spectrometry, ELISA, DAS ELISA, protein immunoprecipitation, immunoelectrophoresis, Western Blot, protein immunostaining, Northern Blot, reverse transcription PCR (RT-PCR), quantitative PCR (q-PCR), RIA (radioimmunoassay), hybridization in situ, nuclease protection assay, mass sequencing, immunocytochemical or immunohistochemical techniques microarray of genomic DNA, protein microarray, messenger RNA microarray, cDNA microarray, peptide microarray, tissue microarray, cell or transfection microarray, antibody microarray, lysate or serum microarray, reverse phase protein microarray, microarray of genotyping peptides or microarrays.
    类似技术:
    公开号 | 公开日 | 专利标题
    Ma et al.2019|CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis
    Liu et al.2016|AURKA induces EMT by regulating histone modification through Wnt/β-catenin and PI3K/Akt signaling pathway in gastric cancer
    ES2727904T3|2019-10-21|Method for the prognosis and treatment of metastatic bone cancer that originates from breast cancer
    JPWO2014017491A1|2016-07-11|Fusion gene of CEP55 gene and RET gene
    EP2510121A1|2012-10-17|Phosphatidylinositol-3-kinase pathway biomarkers
    Weng et al.2017|PTTG3P promotes gastric tumour cell proliferation and invasion and is an indicator of poor prognosis
    Ryuge et al.2013|The clinicopathological significance of Lgr5 expression in lung adenocarcinoma
    ES2870096T3|2021-10-26|Biomarkers of response to EZH2 inhibitors
    US9523691B2|2016-12-20|Use of the olfactomedin-4 protein | in colorectal cancer diagnosis
    Liu et al.2016|miR‐302b regulates cell cycles by targeting CDK 2 via ERK signaling pathway in gastric cancer
    US20200283856A1|2020-09-10|Prognostic and diagnostic methods for colorectal cancer
    Chen et al.2018|High expression of WWP1 predicts poor prognosis and associates with tumor progression in human colorectal cancer
    Men et al.2015|Cullin7 is required for lung cancer cell proliferation and is overexpressed in lung cancer
    US20180051344A1|2018-02-22|Embryonic isoforms of gata6 and nkx2-1 for use in lung cancer diagnosis
    Zhang et al.2016|Functional characterization of the tumor suppressor CMTM8 and its association with prognosis in bladder cancer
    Yang et al.2020|Methylation-induced silencing of ALDH2 facilitates lung adenocarcinoma bone metastasis by activating the MAPK pathway
    ES2696798B2|2019-07-08|N-CADHERINA AND FGFR1 AND / OR FGFR4 FOR USE IN THE PREDICTION OF PATIENTS &#39;RESPONSE TO TREATMENT OF LUNG AND METHOD CANCER AND KIT BASED ON SUCH USE
    Ciuffi et al.2019|Characterization of a novel CDC73 gene mutation in a hyperparathyrodism-jaw tumor patient affected by parathyroid carcinoma in the absence of somatic loss of heterozygosity
    Wang et al.2020|AURKB promotes the metastasis of gastric cancer, possibly by inducing EMT
    Cui et al.2019|RETRACTED ARTICLE: The value of FGF9 as a novel biomarker in the diagnosis of prostate cancer
    WO2019012174A1|2019-01-17|Pegfr and fgfr1 and/or fgfr4 for use in the prediction of the response of patients to a lung cancer treatment and method and kit based on said use
    Han et al.2020|Yes-Associated Protein Contributes to Cell Proliferation and Migration of Gastric Cancer via Activation of Gli1
    Zheng et al.2019|Growth‐associated protein 43 promotes thyroid cancer cell lines progression via epithelial‐mesenchymal transition
    Pavón et al.2019|The combined use of EFS, GPX2, and SPRR1A expression could distinguish favorable from poor clinical outcome among epithelial‐like head and neck carcinoma subtypes
    Xu et al.2019|Rh type C-glycoprotein functions as a novel tumor suppressor gene by inhibiting tumorigenicity and metastasis in head and neck squamous cell carcinoma
    同族专利:
    公开号 | 公开日
    EP3636773A4|2021-03-03|
    ES2696798B2|2019-07-08|
    WO2019016422A1|2019-01-24|
    US20210164053A1|2021-06-03|
    EP3636773A1|2020-04-15|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US8709718B1|2011-02-12|2014-04-29|Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.|Method of treating lung cancer|
    US20150335643A1|2014-05-20|2015-11-26|Roman K. Thomas|Personalized treatment of cancer using fgfr inhibitors|
    JP5240739B2|2007-04-13|2013-07-17|オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー|Biological markers that predict anticancer responses to kinase inhibitors|
    EP2695950A1|2012-08-10|2014-02-12|Blackfield AG|Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor|KR102315706B1|2020-03-30|2021-10-21|한국원자력의학원|Biomarker composition for predicting cancer malignant prognosis induced by microplastic exposure|
    法律状态:
    2019-01-17| BA2A| Patent application published|Ref document number: 2696798 Country of ref document: ES Kind code of ref document: A1 Effective date: 20190117 |
    2019-07-08| FG2A| Definitive protection|Ref document number: 2696798 Country of ref document: ES Kind code of ref document: B2 Effective date: 20190708 |
    优先权:
    申请号 | 申请日 | 专利标题
    ES201730929A|ES2696798B2|2017-07-13|2017-07-13|N-CADHERINA AND FGFR1 AND / OR FGFR4 FOR USE IN THE PREDICTION OF PATIENTS 'RESPONSE TO TREATMENT OF LUNG AND METHOD CANCER AND KIT BASED ON SUCH USE|ES201730929A| ES2696798B2|2017-07-13|2017-07-13|N-CADHERINA AND FGFR1 AND / OR FGFR4 FOR USE IN THE PREDICTION OF PATIENTS 'RESPONSE TO TREATMENT OF LUNG AND METHOD CANCER AND KIT BASED ON SUCH USE|
    PCT/ES2018/070501| WO2019016422A1|2017-07-13|2018-07-13|N-cadherin and fgfr1 and/or fgfr4 for use in predicting the response of patients to a lung cancer treatment and method and kit based on said use|
    US16/630,021| US20210164053A1|2017-07-13|2018-07-13|N-cadherin and fgfr1 and/or fgfr4 for use in predicting the response of patients to a lung cancer treatment and method and kit based on said use|
    EP18836033.3A| EP3636773A4|2017-07-13|2018-07-13|N-cadherin and fgfr1 and/or fgfr4 for use in predicting the response of patients to a lung cancer treatment and method and kit based on said use|
    [返回顶部]